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Resumo 
Durante a última década, uma vasta gama de formulações para a administração oral de fármacos 
anticancerígenos tem sido utilizada na prática clínica. No entanto, este desenvolvimento é dificultado 
pela baixa solubilidade nos fluidos gástricos e intestinais e consequente diminuta biodisponibilidade 
destes fármacos. Assim, o uso de veículos transportadores de fármacos, como as micelas poliméricas, 
está a ser amplamente investigado como estratégia de formulação devido à sua capacidade de 
encapsular fármacos de forma estável e com grande eficiência, aumentando a sua solubilidade e 
possibilitando ainda a sua penetração nos tecidos devido ao seu pequeno tamanho. Nesta dissertação, 
foram produzidas micelas poliméricas à base de quitosano (CS) e policaprolactona (PCL) com o 
objetivo de melhorar o perfil farmacocinético do paclitaxel (PTX), após a administração oral. 
Copolímeros de quitosano e policaprolactona (CS-g-PCL) foram sintetizados através de uma reação 
carbodiimida por amidação sendo caracterizados por transformada de Fourier de espectroscopia de 
infravermelho (FTIR), análise de ressonância magnética nuclear (RMN) e ângulo de contacto. Os 
resultados sugerem a formação do copolímero através do aparecimento de bandas amidas no espetro 
de FTIR, pelo aparecimento dos picos de ambos os polímeros no espectro do novo copolímero na 
análise de RMN e ainda pela maior hidrofobicidade quando em contacto com a água. Averiguou-se a 
concentração micelar crítica (CMC) do copolímero formado pelo método condutimétrico, obtendo-se 
a concentração de 3.7 × 10−3 mg/mL. A caracterização morfológica das micelas foi realizada por 
microscopia eletrónica de transmissão (TEM) e a determinação do diâmetro médio, índice de 
polidispersão e carga superficial foram determinados por espalhamento de luz dinâmico (DLS) e 
espalhamento de luz eletroforético (ELS), respetivamente, obtendo-se valores de 408 nm, 0,335 e 
30,9 mV para a formulação otimizada, escolhida para os ensaios subsequentes. A eficiência de 
encapsulação (82%) foi determinada por cromatografia líquida de alta performance (HPLC). O perfil 
de libertação do PTX encapsulado nas micelas e do PTX livre foi estudado in vitro em condições 
intestinais simuladas. Verificou-se que as micelas controlaram a libertação por até 8 h. A 
citotoxicidade dos polímeros CS e PCL, do copolímero, das micelas com PTX encapsulado e o PTX livre 
foi testada contra células epiteliais intestinais (HT29-MTX e Caco-2). Verificou-se ausência de 
toxicidade para os polímeros isoladamente nas concentrações testadas. O copolímero apresentou 
toxicidade à maior concentração testada (1 mg/mL). O aumento da concentração de PTX livre e de 
micelas com PTX encapsulado levaram à diminuição da viabilidade celular, contudo, o sistema micelar 
apresentou sempre menor toxicidade em comparação com o fármaco livre. Por fim, foi realizado o 
ensaio de permeabilidade para o fármaco livre e para o sistema micelar em modelo de monocultura 
de células Caco-2 e em modelo de co-cultura de células Caco-2/HT29-MTX. Verificou-se que o sistema 
micelar desenvolvido teve uma permeação superior ao fármaco livre nos dois modelos intestinais 
testados. Assim, o sistema micelar desenvolvido mostrou ultrapassar as barreiras fisiológicas com 
desempenho superior ao anticancerígeno atualmente utilizado em terapia clínica. Pode concluir-se 
que o sistema micelar realizado no âmbito desta dissertação apresenta potencial para ser utilizado 
como sistema de libertação de fármacos hidrofóbicos, nomeadamente fármacos anticancerígen
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Abstract 
During the last decade, a wide range of formulations for oral administration of anticancer drugs have 
been used in clinical practice. However, this development is sometimes hampered by low solubility 
in gastric and intestinal fluids and consequent decrease in bioavailability of these drugs. Thus, the 
use of drug carriers, such as polymeric micelles, is being widely investigated as strategy of formulation 
due to its ability to encapsulate drugs in a stable way with great efficiency, increasing its solubility 
and also allowing tissue penetration due to their small size. In this dissertation, polymeric micelles 
were produced based on chitosan (CS) and polycaprolactone (PCL) in order to improve the 
pharmacokinetic profile of paclitaxel (PTX) after oral administration. Chitosan-grafted-
polycaprolactone (CS-g-PCL) copolymer was synthesized through a carbodiimide reaction by amidation 
being subsequently, characterized by Fourier Transform Infrared Spectroscopy (FTIR), Nuclear 
Magnetic Resonance analysis (NMR) and contact angle. The results suggest the formation of a new 
copolymer by the appearance of amide bands in the FTIR spectrum, appearance of both polymers 
peaks in the new copolymer spectrum in NMR analysis and, also higher hydrophobicity when in contact 
with water. The critical micelle concentration (CMC) of the copolymer, investigated by 
conductimetric method, was 3.7 × 10−3 mg/mL. The micelles morphology was characterized using 
transmission electron microscopy (TEM) and the determination of the average diameter, 
polydispersity index and surface charge were determined by dynamic light scattering (DLS) and 
electrophoretic light scattering (ELS), respectively, obtaining values of 408 nm, 0.335 and 30.9 mV 
for the optimized formulation chosen for subsequent tests. The encapsulation efficiency (82%) was 
determined by high performance liquid chromatography (HPLC). The release profile of free PTX and 
PTX loaded micelles was studied in vitro in simulated intestinal conditions. The micelles were able to 
control the drug release up to 8 hours. The cytotoxicity of CS and PCL polymers, copolymer, the PTX 
loaded micelles and free PTX was tested against intestinal epithelial cells (HT29-MTX and Caco-2). It 
was observed the absence of toxicity to polymers individually for all tested concentrations. The 
copolymer presented toxicity at the highest concentration tested (1 mg/mL). The increase of free 
PTX and PTX loaded micelles led to a decreased of cell viability, however, the micellar system showed 
lower toxicity when compared to the free PTX. Finally, it was performed the permeability assay for 
the free drug and the micellar system in the Caco-2 monoculture model and Caco-2/HT29-MTX co-
culture model. It was observed that the micellar system developed had superior permeation of PTX 
when compared to the free drug in both intestinal models tested. Thus, the micellar system developed 
was able to overcome the physiological barriers with better performance than the anticancer drug 
currently used in clinical therapy. Therefore, it can be concluded that the PTX-CS-g-PCL micelles 
developed in this dissertation is a potential drug carrier for the controlled release of hydrophobic 
drugs, particularly, anticancer agents.
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Chapter 1 
Introduction 
The field of biomedical science is in constant work trying to develop new molecules or drug 
products capable of performing therapeutic functions. A special regard is given to cancer therapy, as 
the cure for tumour diseases is far from being achieved, even with appropriate therapeutic conditions. 
However, much work has been devoted to this area and, gradually, the progress are beginning to be 
notorious.  
1.1 - Context and motivation  
The colorectal cancer is a leading cause of death not only in Portugal, but in the world. Although 
the diversity of treatment methods such as surgery, chemotherapy and radiotherapy, 50% of patients 
are recidivist in the disease [1]. The efficacy of well-established drugs can be improved with the 
support of a biomaterial that confers, for example, adequate solubility and further bioavailability. 
This is the case of many anti-cancer drugs, such as paclitaxel (PTX), with limited efficiency due to low 
solubility.  
PTX is an anticancer drug used in various types of cancer, including colorectal cancer. Its 
mechanism of action affects the cell division, leading to hyper stabilization of microtubules that stops 
mitosis in G2 and M phases, leading to cell death [2]. Besides being a hydrophobic drug and, therefore, 
with low solubility in aqueous environment, its commercial used form, Taxol®, entails drastic side 
effects to patients due to the employment of organic excipients to provide suitable solubilisation. 
Thus, currently, the demand of a biomaterial able to encapsulate such drugs is the major focus of 
research.  
Polymeric micelles can be spontaneously formed in aqueous solution using amphiphilic polymers, 
as result of hydrophobic interactions between the segments of two polymers [3]. These systems have 
the ability to encapsulate in their hydrophobic inner lipophilic drugs and demonstrated better 
response in the treatment of disease due to the capacity of the drug to remain in the systemic 
circulation and the reduction of side effects when compared with the free drug [4]. Moreover, the 
drug can be protected from adverse conditions of the body such as enzymes or biological fluids, 
preserving their stability [5]. 
2 Introduction 
 
 
Chitosan, a natural polymer, has already been described and their properties are primarily based 
on the fact that is biocompatible, biodegradable, non-toxic and have mucoadhesive properties, which 
ensures its permanence on the epithelium [6]. Besides, it is proposed here as the ideal candidate to 
be the hydrophilic component of polymeric micelles due to the presence of reactive groups (NH2, OH) 
on its backbone. Thus, CS can be chemically modified by the addition of hydrophobic groups as 
moieties of polycaprolactone (PCL) allowing the preparation of CS amphiphilic derivatives that are 
able to self-assemble and form stable micelles [7].  
Currently, it is possible to test this type of drug carriers through the intestinal in vitro models 
that mimic very closely the human intestine. These models allow the evaluation of permeability and 
drug absorption of these systems in order to develop a new one that will overcome all those barriers 
hitherto, leading to a therapeutically effective effect. 
1.2 - Objectives 
The main goal of this dissertation was to design a novel polymeric micelles as effective polymer-
based drug delivery systems, achieving a controlled release of the encapsulated drug, PTX, in 
colorectal cancer cells after oral administration. This includes synthetize and characterize a new 
amphiphilic graft copolymer of CS and PCL with self-assembling properties in aqueous environment; 
produce polymeric micelles to encapsulate and enhance the solubility and stability of PTX; 
characterize the physical-chemical properties of micelles and drug kinetics in simulated biological 
media by an in vitro release study; evaluate their toxicity in intestinal cancer cells through the in 
vitro cytotoxicity studies; evaluate the PTX intestinal permeability formulated into polymeric micelles 
and free PTX in cell-based intestinal models developed by our group as an approach to improve the 
pharmacokinetic profile and bioavailability of PTX after oral administration. 
The rationale for the overall concept of the project arises from the idea of developing a new 
biomaterial able to form nanosystems for the incorporation of anticancer drugs and, thus find a system 
capable of operating in the desired target, leading to a therapeutically effective treatment against 
cancer. 
1.3 - Document structure 
This dissertation is organised in five chapters. The first chapter is the Introduction, where the 
context and motivation for this work and the main goals inherent is evaluated. The second chapter is 
the Literature Review, which is divided into seven sections where is addressed the main problem 
proposed for this dissertation, the human intestine architecture as well as the models used to evaluate 
new formulations, a brief description of the anticancer drug used and an approach to polymeric 
micelles as drug carriers as well as a description the polymers that constitute them. Finally, a short 
review is made of the methods used to produce this type of copolymer.  
Material and Methods of the all work performed is presented in chapter 3. The chapter 4 presents 
all the results and discussion of the work. Finally, in the last chapter is presented the main findings 
of this dissertation and referred to future prospects and possible improvements of this work.
 Blank page 
 4 
Chapter 2 
Literature Review 
The use of drug carriers is of upmost importance for drug delivery, being extensively investigated 
in pharmaceutical research. Polymer-based drug delivery systems are promising as they enable 
enhancing therapeutic efficiency, thus, reducing the side effects common to most drugs. This chapter 
will address the issues related to biomaterials used to produce nanosystems for the encapsulation of 
hydrophobic drugs, with special attention to anti-cancer drugs with interest on colorectal tumors. 
2.1 Colorectal cancer 
Cancer is a leading cause of death worldwide and the number of deaths is predictable to continue 
to increase in the next decades. In Portugal, deaths from cancer increased 0.6% compared to the 
previous year, being the second cause of death in 2013 [8]. In total, 25.920 people died of cancer in 
2013 in Portugal, which corresponds to 24.3% of mortality in the country, over 162 deaths in the 
previous year. The colorectal cancer is the second most common type of cancer in both men and 
women in Portugal [8] and the third higher incidence and fourth higher mortality worldwide in both 
genders [9].  
The change in bowel habits (diarrhea or constipation), blood in the stool, abdominal pain, loss of 
appetite or weight loss are some of the most common symptoms that lead to diagnosis. Carcinoma of 
the colon and rectum develops from mucosal epithelial cells of these organs, often from precursor or 
pre-malignant lesions such as polyps. The lower gastrointestinal endoscopy is the method of choice in 
the diagnosis of these tumors because they allow to view the lining of the rectum and colon and 
collect small fragments for analysis for histological confirmation. 
The treatment of colorectal cancer depends on the location, size, and extent of spread of cancer, 
as well as the health of the patient [10]. However, the treatment is based on surgery in combination 
with radiotherapy and/or chemotherapeutic agents such as antimetabolites (5-fluorouracil, 5-FU), 
topoisomerase inhibitors (doxorubicin, DOX), platinum salts (cisplatin) or taxanes (paclitaxel, PTX) 
[11], which is given after surgery. 
Although tumor resection by surgery and conventional chemotherapy, nearly 50% of patients with 
colorectal carcinoma return to develop the disease [1]. This method of treatment becomes less 
effective to the extent that cannot eliminate cancer cell subpopulations with highly aggressive 
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chemotherapy resistance, the ability to increase the heterogeneity of the tumor and metastases 
development [12]. Thus, there is an urgent need to develop new approaches that could improve the 
existing chemotherapeutic treatment. 
The advances in nanotechnology have enabled the delivery of anticancer drugs or 
chemotherapeutic agent through nanocapsules [13], micelles [14] or nanoparticles [15]. These 
transport vehicles have a great potential since they can overcome some barriers, such as the reduction 
of systemic toxicity, improving the solubility of biomolecules, particularly hydrophobic molecules and 
poorly soluble in water [16]. Additionally, these carriers have the ability to prolong the half-life of 
the drug in systemic circulation because of the lack of functional lymphatic drainage and due to the 
large abnormal tumor vasculature, which makes them unable to eliminate the biomaterials that were 
extravagated [17]. Thus, these vehicles tend to accumulate in the tumor over time through a 
mechanism called enhanced permeability and retention (EPR) effect [18, 19]. Particularly, 
mucoadhesive nanoparticles can adhere to the mucus slowing the particle transit time in the gut, 
thereby increasing the time available for the entrapped drug to be released and absorbed. Therefore, 
is expected a larger drug doses to be directly released to the intestine epithelial cells. 
2.2 Intestinal architecture and cell models for permeability 
studies 
Currently, the pharmaceutical industry has a significant interest in the development of in vitro 
human small intestine models in order to evaluate strategies for the improvement the absorption of 
drugs. Thus, the determination of oral absorption is an important part in the development of new 
drug carriers. One approach to a simple and reproducible absorption model is to cultivate intestinal 
cells on permeable membranes, denominated Transwell®. 
2.2.1 Anatomy and physiology of gastrointestinal system 
The principal function of gastrointestinal (GI) tract is digestion and absorption of nutrients and 
vitamins that are ingested through food. The GI tract is arranged in order to facilitate this and others 
functions, being designed to prevent the entry of pathogens or undigested macromolecules. Actually, 
about 90% of the GI tract absorption occurs in the small intestine [20]. 
The intestinal tract begins after the stomach with the small intestine (duodenum, jejunum and 
ileum) and the large intestine (colon). Each part of the GI tract have anatomical, biochemical and 
physiological properties which command the parameters of digestion and absorption. Intestine wall is 
composed of layers that are not fully separated from each other, but are joined together by 
connective tissue and vascular and neuronal elements [21]. As can be seen in Figure 2.1, the GI tract 
is divided into four layers: 1) the mucosa (which is subdivided into epithelium, lamina propria, and 
muscularis mucosae), 2) the submucosa, 3) the muscularis propria and 4) the serosa.  
Mucosa, the innermost layer, is the structural layer and functionally more complex and important 
because is where absorption occurs. Thus, the mucosa consists of three layers: a first coating layer 
comprises epithelial cells that are bathed in nutrients, commensal bacteria and mucus [22]. The 
epithelium is connected to the basal membrane covering the second layer, lamina propria. This layer 
consists of subepithelial connective tissue, blood capillaries and lymph nodes [21]. The third and 
deepest layer called the muscularis mucosae, which is constituted by a thin layer of smooth muscle. 
The submucosa lies between the mucosa and the muscularis propria. The last one is where longitudinal 
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and circular muscle is present with the goal of boost food through initiation of contractile peristaltic 
waves regulated by neuronal and hormonal form [23]. The outermost layer is referred to as the serosa 
which is a protective layer against spread of inflammatory and malignant processes [24]. 
Figure 2.1 – Organization of digestive tract by layers: mucosa, submucosa, muscularis propria and serosa. 
Adapted from [25]. 
 
The epithelium of the small intestine consists of four different cell lines: cells that take up the 
villi (enterocytes, goblet cells and enteroendocrine) and differentiated cells that reside at the bottom 
of the crypts and secrete antimicrobial agents, Paneth cells and microfold cells (M-cells) [21, 26] (see 
Figure 2.2A). Crypts are tubular invagination of the intestinal epithelium being characterized by 
presenting in its base Paneth cells and stem cells, which continuously divide and are the source of all 
intestinal epithelial cells [26]. Already the villi are tiny finger-like projections, which increase the 
surface area by approximately 30-fold, being characterized by the presence of mature enterocytes, 
goblet cells and mucus secreting [27]. 
The human colon is very similar in its cellular organization and morphology to the small intestine 
as depicted in Figure 2.2B. The large intestine or colon begins in the right iliac region of the small 
intestine. Unlike the small intestine, the mucosa of the large intestine is not covered with villous 
projections but contains deep tubular pits, which increase in depth as they approach the rectum, as 
well as the muscularis propria and further increase the surface area for digestion and absorption by 
approximately 600-fold [21].  
The epithelial cells of the colonic mucosa include enterocytes (absorptive cells), enteroendocrine 
cells, epithelial stem cells, goblet cell and microfold cells (M-cells) [21], nearly identical to cells in 
the small intestine.  
All types of cells mentioned above have distinct functions: 
a) Enteroendocrine cells: specialized endocrine cells of the gastrointestinal tract that 
differentiate from pluripotent stem cells with ability to coordinate the functioning of the 
intestine by specific hormone secretion; 
b) Paneth cells: specialized cells that reside in the crypts and has a role in innate immunity 
through the secretion of proteins; 
c) Goblet cells: produce and secrete mucins, which constitutes the mucus need for chemical 
and mechanical protection of the intestine; 
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d) Enterocytes: are columnar and highly polarized cells, and characterized by the presence of 
an apical brush border, which perform the around 80% of the absorption of nutrients through 
the epithelium [22, 28, 29]; 
e) M cells are specialized in transepithelial transport of macromolecules, particles and 
microorganisms. 
Figure 2.2 – Schematic representation of the architecture of the small intestine (A) and the colon (B) as well as 
all the cell types present in an intestinal villus. Adapted from [26]. 
2.2.2 Pathways through the intestinal epithelial barrier 
Oral administration of therapeutic agents is the most common and preferred route of drug delivery 
for patients, in view of their ease of administration. However, drugs administered orally, as compared 
to those administered parenterally, are not directly available in the systemic circulation to make its 
therapeutic effect effective. Following oral administration of a drug, there are many barriers which 
the drug must pass to be absorbed by the intestine. Starting with the drastic pH changes at slightly 
acidic (pH 1.2-3.0) in the stomach to slightly alkaline (pH 6.5-8.0) in the end of the ileum proximal, 
lead to drastic changes of stability and solubility of the drug [27]. In the small intestine, which is the 
main site of absorption, the enzyme activity collects a number of proteolytic enzymes which may 
degrade the drug [27, 30]. In addition to the above parameters, molecular size, 
lipophilicity/hydrophilicity, site of action, efflux pathways and stability/solubility of the administered 
drug are others factors to be considered when considering administration of therapeutic oral agents. 
A B 
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There are several absorption pathways in the intestinal epithelium such as by passive diffusion, 
which occurs through nonspecific permeability pathways (for small amphipathic molecules), by the 
paracellular route (to hydrophilic molecules of low molecular weight), specialized carriers to effect 
the facilitated absorption of molecules (sugars and amino acids) [27], among others (see Figure 2.3). 
Since larger molecules such as peptides, proteins and anticancer drugs can be absorbed by endocytosis 
[31].  
Figure 2.3 – Schematic representation of the transport across the intestinal epithelium. Molecules can across the 
intestinal epithelial barrier by paracellular transport (blue line) and by transcellular transport through passive 
diffusion (green line), transcytosis via normal enterocytes (yellow line) or via M-cells (red line). 
 
Some reports demonstrated that particles with about 100-200 nm could be internalized by the 
receptor-mediated endocytosis, whereas large particles have to be phagocytized [32]. On the other 
hand, larger molecules must be transported by paracellular route, which corresponds to the passage 
of molecules across epithelial cells. Consequently, tight junctions (TJs) should open to occur this 
passage with biomaterials such as chitosan (CS) that have this ability [33]. Actually, the movement 
through the epithelium can occur the apical to basolateral side, which corresponds to the movement 
from the intestinal lumen to underlying tissue and circulation, and on the contrary, to the basolateral 
to apical side. The epithelium, reinforced by TJs and efflux transporters, exclude molecules larger 
than 200 Da via paracellular transport [34].  
The TJs are an adhesion region between adjacent epithelium (endothelial cells) that regulates 
the paracellular flow. There are several proteins in this adherence area that are responsible for 
opening and closing it [26]. The combined role of P-glycoprotein (P-gp) which is an efflux pump family 
of adenosine triphosphate (ATP) binding cassette transporter and acts contrary to the absorption of 
drugs [35], with cytochrome P450 3A, an enzyme that metabolizes drugs has been recognized as one 
of the main determinants of intestinal wall absorption [36]. Still, even when administered a significant 
amount of drug and is carried to the intestinal epithelium, the first pass metabolism by the liver will 
reduce substantially the initial dose to a dose fraction which will pass, later, to the systemic 
circulation [37]. 
For these reason, the use of polymeric micelles as drug carriers is a promise to overcome these 
and other barriers and reach the target with less degradation and maximum quantities. The opening 
of the intestinal cell barrier, through a breakdown of TJs, can increase the absorption of drugs 
delivered orally.  
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2.2.3 Intestinal in vitro models 
Since in vivo studies are complex and time consuming, gastrointestinal digestion and intestinal 
absorption in vitro models have been developed [22, 38, 39].  
Caco-2 cells (Figure 2.4A), derived from human colon adenocarcinoma, are very used as model 
to mimic human intestinal epithelium and study intestinal absorption of drugs, as these cells suffer 
spontaneous enterocytic differentiation in culture and are polarized with well-established TJs [20]. 
Also, Caco-2 cells present apical brush border with abundant microvilli and enzymatic activity of 
digestive enzymes such as  alkaline phosphatase (ALP) [22]. Since the permeation of drugs across 
monolayers of Caco-2 cells are close to the characteristics of permeation of human intestinal mucosa, 
this model has been suggested for predicting oral drug absorption in humans [20]. However, our group, 
started to use C2BBe1, a clone of Caco-2, as is described in even better mimic the enterocyte because 
the parental Caco-2 cells have an heterogeneous population not displaying always the brush border 
typical of the enterocytes [40].   
Similarly, HT29 cell lines has its origin in human colorectal adenocarcinoma, and, after 21 culture 
can be differentiated into goblet cells, mimicking them [22]. Because of HT29 cells acquire a 
heterogeneous phenotype when cultured in modified medium [41], Lesuffleur established HT29-MTX 
cell line in a medium containing 10-6 M methotrexate (MTX) (see Figure 2.4B). This cell line grows in 
a monolayer of polarized goblet cells that produce mucus, it has a discrete apical brush border with 
intestinal hydrolases and, contrasting with Caco-2 cells, do not express P-gp and have less TJs [41]. 
The main physiological function of mucus includes protecting the GI epithelium itself to be degraded 
by stomach acid and digested by gastric and intestinal enzymes. 
Figure 2.4 – Morphological aspect of Caco-2 cells (A) and HT29-MTX cells (B) at a resolution of 20 µm. The images 
were taken with Nikon TE2000-U microscope equipped with digital camera and controlled via the Nikon ACT-1 
program. 
 
The Transwell® system comprises a well of a plate with an insert inside and represents a potential 
in vitro tool for investigating intestinal permeability lumen-to-blood drug, i.e., the permeability from 
apical compartment to the basolateral compartment (Figure 2.5). It is necessary to use human cell 
lines, preferably several lines of cells, with the goal of reproducing the intestinal heterogeneous 
population, mimicking better the human intestine [22]. The insert of this system includes a 10 mm 
thick membrane made of polyester or polycarbonate and is available with different pore sizes.  
A B 
20 µm 20 µm 
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Figure 2.5 – Schematic representation of a Transwell® that consist in a well plate plus insert. The epithelial cells 
are seeded on the top of the membrane where the compounds are placed and the permeability occurs the apical 
to the basolateral compartment. 
 
The integrity of each model can be easily monitored by measuring the transepithelial electrical 
resistance (TEER) which returns the absolute values of resistance per unit area [22]. The higher the 
value of TEER more TJs exist to modulate the transport of molecules by paracellular route. 
2.2.3.1 Caco-2 model 
Due to all the features described about the Caco-2 cell lines, the monoculture of these cells is 
the standard for the intestinal absorption in in vitro models.  
As already mentioned, Caco-2 cells undergo spontaneous differentiation in the enterocyte, 
however, in the early stages of the culture (3-4 days), Caco-2 cells remain undifferentiated, showing 
only some apical microvilli [22]. Thus it is necessary to culture the cells as a monolayer for around 21 
days to produce the differentiation into enterocytes, which are the main important cells in human 
intestine, able to form junctions between cells. Although they are derived from colon, they express 
most of the morphological and functional characteristics of the intestinal absorption cells, including 
enzymes typically expressed in enterocytes [22]. 
Some disadvantages are evident in this model, for example, no mucus production and no 
differentiation between cellular transport and intestinal metabolism [42], there is a high and variable 
P-gp expression and a low expression of metabolic enzymes [43], and the permeability of hydrophilic 
compounds is made by paracellular route, which makes this model less efficient because of TJs as 
compared with the human or animal intestine [42]. In this case, the Caco-2 model is used to 
investigate their utility in the study of passive absorption of drugs (Figure 2.6). 
 
Figure 2.6 – Schematic representation of the Caco-2 monoculture model setup. 
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2.2.3.2 Caco-2/HT29-MTX model 
To overcome some barriers of the model mentioned above, a new model was imposed. This model 
consists in a mixture of Caco-2 and HT29-MTX (mucus-producing) cell lines with the aim to generate 
more predictable results (see Figure 2.7). 
Once HT29-MTX cells do not form TJs as tight as Caco-2 cells when cultured in monolayer, is given 
an increase in paracellular transport routes, making the model closer to the human intestine [44].  
Also, the mucus production is important because it protects the organism against the entry of 
pathogens agents, however, acts as a barrier to absorption of drugs, affecting the retention time of 
the compound in the intestinal wall [45].  
This co-culture model was studied by our group and it was found that the optimum ratio to obtain 
a closer mimic reality is 90% Caco-2 cells and 10% of HT29-MTX cells [38]. 
 Figure 2.7 – Schematic representation of the Caco-2/HT29-MTX co-culture model setup. 
2.2.3.3 Caco-2/HT29-MTX/Raji B model 
A more realistic and complexed model is based on Caco-2 cells, HT29-MTX and Raji B, originally 
developed by our group [38, 44]. 
Raji B cells are derived from a human Burkitt's lymphoma, and when cultured with Caco-2 cells, 
these are induced to M-cell phenotype, resembling, functionally and morphologically to intestinal M-
cells characterized by scarce and irregular microvilli [29] [38]. Since the presence of lymphocytes 
leads to the formation of cells that resemble intestinal M-cells in function and morphology, 
contributing to the transport of nanoparticles, and combined with the advantages of the co-culture 
model showed above, this model mimics even more by human intestinal epithelium. 
Once M-cells are specialized in transepithelial transport of macromolecules, particles and 
microorganisms, this model is more complete compared to the models described above as will mimic 
more adequately the human intestine for development of new drugs administered orally also more 
suitable and closer to the in vivo model. 
2.3 Anticancer drug model - Paclitaxel 
Paclitaxel (PTX), a large antineoplastic agent isolated from the bark of Pacific Yew (Taxus 
brevifolia from family Taxaceae), is characterized for its potent anti-tumor capabilities against a 
broad spectrum of cancers, such as metastatic breast cancer, colon cancer, ovarian cancer, among 
others [46]. PTX is a white to off white crystalline powder, highly hydrophobic and insoluble in water 
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and has the molecular formula C47H51NO14 (Figure 2.8), which corresponds to a molecular weight (Mw) 
of 853 Da. 
 
Figure 2.8 – Chemical structure of paclitaxel. Adapted from [2]. 
 
Its mechanism of action is promoted by the polymerization of tubulin and hyper stabilization of 
microtubules in their polymerized form, leading to cell death [47, 48]. Microtubules are an integral 
component of eukaryotic cells and are involved in various cellular functions including mitosis, 
maintaining the form and movement of the cell, organelle transport between the cell interior and 
spindle formation during cell division. On the other hand, tubulin is a protein that form the 
microtubules. PTX alter the normal balance, forcing the polymerization of tubulin dimers leading to 
the formation of microtubules, making them stable by preventing depolymerisation and, therefore, 
making them dysfunctional [48]. Consequently, interrupts cell division, since the stabilization of 
microtubules interferes with the G2 and M phases of the cell cycle (and these cellular activities 
involves microtubules), causing cell death by disrupting the normal dynamics of the tubule needed 
for cell division and vital interphase process [2, 48] (see Figure 2.9). 
Figure 2.9 – Schematic representation of cell cycle. Adapted from [49]. 
 
PTX is poorly soluble in aqueous medium, but can be dissolved in organic solvents such as dimethyl 
sulfoxide (DMSO) (50 mg/mL) and methanol (50 mg/mL) [50], and acetonitrile (15 mg/mL) and ethanol 
(40 mg/mL) [2]. This drug is rapidly destroyed in weakly alkaline medium, methanolic solutions and 
in strongly acidic methanolic solutions. For instance, a sample with 0.1% acetic acid added to 
methanol showed no signs of degradation for 7 days at room temperature (RT) or during 3 months at 
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4 ºC [51]. Due to the low solubility and poor permeability of PTX, it is classified under class IV of 
Biopharmaceutic Classification System (BCS) [52], which means being slightly permeable by the 
intestinal mucosa in addition to the poor solubility, as already discussed. 
The commercial form of PTX, Taxol®, is designed in a vehicle consisting of Cremophor EL 
(polyethoxylated castor oil) and dehydrated ethanol (50:50, v/v) [53]. This form is clinically used 
after dilution in isotonic saline solution before intravenous administration (i.v.). However, a drastic 
number of side effects are reported as hypersensitivity, peripheral neuropathy, hypotension, 
neurotoxicity, nephrotoxicity [54], among others. Furthermore, i.v. may cause other problems such 
as infections and thrombosis. Therefore, several alternatives to the use of Cremophor EL-based 
vehicle have been explored to reduce these and other side effects and improve the therapeutic 
efficacy of PTX. One such alternative is polymeric micelles [55] to be administered orally as it is the 
most cost-effective treatment method due to less need for visits and remained in the hospital staff 
and for the preparation and administration of the treatment. 
The half maximal inhibitory concentration (IC50) is a measure of the effectiveness of a substance 
in inhibiting a specific biological or biochemical function by half. The IC50 of PTX is in the range of 
2.5-7.5 nM [56]. It is important to have knowledge of this value because it indicates the amount of 
PTX required to inhibit a particular biological process by half, in this case, to inhibit cell division. 
Clinically, the dose generally accepted is 200-250 mg/m2 [2]. 
Studies conducted in HeLa cells (from human cervical cancer origin) and fibroblasts using PTX 
(0.25-10 mM) showed that PTX blocked cells in the G2 and M phase of the cell cycle [57]. Already in 
human colorectal cell lines (HCT116) at PTX concentration of 3-10 nM, there was inhibition of mitosis 
leading to cell death [58].  
In general, the PTX in vitro activity is greater than the activity of cisplatin, DOX, and 5-Fu against 
human tumors and equal to or less than docetaxel [46]. 
2.4 Polymeric micelles as drug delivery vehicles 
Polymeric micelles are amphiphilic polymers that could be self-assembled into a core-shell 
nanostructure based on hydrophobic and hydrophilic segments with a range of diameters of 10-200 
nm [59, 60]. This micellar system has the advantage of improve stability in the bloodstream, large 
capacity encapsulation, despite the reduced size, are not toxic and yet have a controlled release of 
the drug [61]. The time of drug circulation in the blood is higher [18, 19], providing better 
permeability to anticancer drugs by improving its delivery from the deep blood vessels to tumors [17]. 
Additionally, these carriers are typically accumulated in extensive vasculature sites, such as solid 
tumors and sites of inflammation, due to EPR effect [18, 19], as already mention above.  
The fact that these systems are organized in core-shell type structures, make them selected for 
drug delivery applications. The stability of these processes is given by the decrease of the Gibbs free 
energy, which makes these systems thermodynamically more stable, this process is called self-
assembly [62, 63]. For being an amphiphilic system, the hydrophobic moiety is protected from the 
aqueous medium, and therefore the hydrophilic part is in contact therewith (see Figure 2.10). The 
hydrophobic core provides space for the encapsulation of hydrophobic drugs such as PTX or DOX, and 
the hydrophilic shell allows the inclusion of hydrophobic drugs and it also provides stability, protecting 
from biological environment [64]. Taking in account these properties, polymeric micelles have 
become a promising carriers of hydrophobic drugs. They are not easily absorbed in the GI tract, 
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providing the reduction of the side effects and they are protected from environmental stimuli such 
as enzymes and gastric pH [16, 65].  
Figure 2.10 – Schematic representation of drug encapsulation from self-assembled nanosystems. 
 
Chemical modifications of polymers are the most efficient and well-known method to create self-
assembled systems. These changes lead to the formation of amphiphilic polymer derivatives by the 
addition of hydrophobic groups, such as alkyl and acyl groups, to the hydrophilic polymer backbone. 
These target drug delivery systems are developed to prevent drug degradation, as well as their loss, 
to avoid the harmful side effects and to increase the bioavailability of the drug in the required site 
of interest [16]. 
If the external components of micelles are usually comprised by hydrophilic polymers as 
polyethyleneglicol (PEG) or chitosan (CS),  to form the micellar core, it has been used various 
polyesters such as poly (L-lactide), poly(glycolic acid-lactide) and PCL [65]. The latter have 
advantages over others polyesters by always keeping elastic at RT, which makes it highly permeable 
[66, 67], and decomposes more slowly, being optimal for controlled release drugs [3]. 
There are two concepts that have to be explained about micelles: the first is the critical micelle 
concentration (CMC), which is the minimum concentration required for a given polymer to form 
micelles by self-assembly. The second is the critical aggregation concentration (CAC), which is the 
minimum concentration required for a given polymer to aggregate. Typically, the CMC values are 
higher than the CAC value [68]. The CMC of the polymer-based micelles depends on the hydrophobic 
character of the molecule [69] and a Mw of the blocks [70]. There are several methods to calculate 
the CMC, such as by conductivity measurements, interfacial tension or fluorescence spectroscopy 
[64]. However, in the case of polymer-based micelles, the CMC is very low, being the fluorescence 
spectroscopy the best choice because of its high sensitivity [64].  
The hydrodynamic diameter of polymeric micelles is possible to be determined by dynamic light 
scattering (DLS) method [71] and the morphology of the micelles can be visualized by transmission 
electron microscope (TEM) and by scanning electron microscope (SEM) methods [60]. Differing the 
composition and size of the micelles of hydrophobic segments and hydrophilic of the materials that 
compose them, it is possible to regulate the properties of the micelles as the size and loading capacity 
[60]. 
2.5 Chitosan and amphiphilic derivatives 
Polysaccharides are widely distributed in nature and, among them, CS is receiving increasing 
attention. CS is a linear polysaccharide prepared from chitin, which is the second most abundant 
natural polymer in the world, after cellulose [72, 73]. Chitin can be found in the exoskeleton of 
Hydrophilic polymer 
Hydrophobic group (graft) 
Drug 
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insects, crustaceans and some cell wall of fungi. CS, derivatived from chitin, can be obtained by 
alkaline deacetylation or enzymatic hydrolysis [73]. The reaction product is CS only when the average 
degree of acetylation (DA), is equal to or less than 50%. The DA is used to characterize the average 
content of N-acetyl-D-glucosamine units (acetylated unit) while degree of deacetylation (DD) is the 
number of D-glucosamine units (deacetylated unit) [7, 72]. Thus, CS is constituted by N-acetyl-D-
glucosamine (GlcNAc units) and of D-glucosamine units (GlcN units), linked by glycosidic linkages β-
(1,4) (Figure 2.11) [6, 72-74]. 
This polymer shows solubility in moderately acidic medium. Its solubility in acidic medium occurs 
due the protonation of the NH2 functional group on the C-2 position of the D-glucosamine repeating 
unit [72, 74, 75].  
CS has one amino group and two hydroxyl groups in the repeating glycosidic residue, providing 
reactive sites for a variety of reactions, which is an advantage over other polymers [76]. Several types 
of CS can be obtained and with different physicochemical properties such solubility, pKa and viscosity, 
which depend on parameters like DD and Mw [73, 77, 78]. 
Figure 2.11 – Deacetylation of chitin to chitosan. 
The DD and the Mw are two of the most important physicochemical properties of this polymer. An 
increase on the DD, leads to an increase of its viscosity, due to high and low deacetylated CSs having 
different conformations in aqueous solutions [79]. Additionally, the CS solution viscosity can be also 
affected by factors as temperature and concentration [79]. For example, when CS concentration 
increases or the temperature of the solution decreases, the viscosity increases.  
CS is a polycation whose charge density depends on DA and pH. Due to the progressive amine 
protonation of pendant groups, the solubility is pH dependent. Therefore, CS is only soluble at pH 
values of approximately 6 or less [6, 75, 80]. This feature turns CS into biopharmaceutical of interest, 
along  with its properties of mucoadhesiveness and ability to open epithelial TJs [33]. In fact, at low 
pH (<6), CS amine groups are protonated and become positively charged, leading to polycationic 
behavior [7, 81]. By contrast, at a higher pH value (above around 6), CS amines are deprontonated 
and reactive (Figure 2.12). 
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Figure 2.12 - The soluble–insoluble transition of chitosan occurs at about pH 6. 
To improve CS solubility in physiological media, its biological properties and expand its potential 
applications, CS derivatives have been synthesized [13-15, 55, 82-84]. Indeed, macromolecules with 
amphiphilic character have become a subject of great interest over the last years. 
2.5.1 Biological properties of chitosan 
CS is a polymer of great interest in pharmacy, medicine and tissue engineering due to its biological 
activities such as non-toxicity [85-88], antimicrobial activity [72, 73, 89-92], biocompatibility [7, 93, 
94], biodegradability [7, 95-97], mucoadhesiveness and ability to open, temporarily, the tight 
junctions of the epithelium [94, 98, 99], thereby facilitating the permeation of drugs [6, 100-103]. 
These properties may double the therapeutic effects making CS a polymer with pronounced potential 
for biomedical and biopharmaceutical applications, especially for drug delivery.  
The presence of NH2 groups in CS is the reason why it exhibits much higher potential as compared 
with chitin [7] and what makes it an excellent polymer for pharmaceutical applications. Also, as 
shown in Table 2.1, it is possible understand the CS biological properties and the relationship between 
its structural characteristics (DD and Mw). For instance, the lower the DD and Mw, the higher the CS 
biodegradability [7, 95-97]. Moreover, CS plays a role in hemostasis, but independently of the 
coagulation cascade [96]. Okamoto and colleagues showed that CS reduces clotting time in a dose-
dependently manner, with the ability to aggregate platelets [104]. 
Table 2.1 — Biological and structural properties of chitosan. 
Property Structural characteristicsa References 
Biodegradability ↓ DD, ↓ Mw [7, 95-97] 
Biocompatibility ↑ DD [7, 93, 94] 
Cytocompatibility ↑ DD [7, 93] 
Mucoadhesion ↑ DD, ↑ Mw [94, 98, 99] 
Hemostatic action ↑ DD [73, 105, 106] 
Analgesic action ↑ DD [107, 108] 
Antimicrobial activity ↑ DD, ↑ Mw [72, 73, 89-92] 
Antioxidant activity ↑ DD, ↓ Mw [72, 109-111] 
a ↑ – Directly proportional to property; ↓ – inversely proportional to property. 
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The properties of CS mentioned above make the CS an exciting and promising excipient for the 
pharmaceutical industry, with a large margin for development. However, CS amphiphilic derivatives 
have, indeed, attracted the particular attention among researchers working in biomedical 
engineering, and particularly, in drug delivery, given the fact that they improve physical and chemical 
properties of CS when used alone [77]. 
2.5.2 Chitosan amphiphilic derivatives 
A large number of CS amphiphilic derivatives have been reported in the literature over the past 
years. CS amphiphilic derivatives result from the attachment of hydrophobic structures to the 
hydrophilic CS backbone due to the presence of hydroxyl and amine groups, and can be achieved by 
using different methodologies such as alkylation [112-115] and acylation [62, 116-123] . Generally, 
the chemical derivatization of CS can be regioselective due to the presence of reactive sites C2-
amine, C3-hydroxyl and C6-hydroxyl. The properties of products of the regioselective reactions are 
strongly influenced by the distribution of substituents groups along the polymer chain and, therefore, 
it is possible to obtain N-substituted, O-substituted or N,O-substituted CS derivatives. In general, the 
reaction products of an amphiphilic CS are, among others, N-alkyl chitosan, acyl-chitosan and graft 
derivatives. Interestingly, the introduction of a hydrophobic molecule on CS backbone modifies its 
rheological behavior, being therefore used as rheological modifiers in pharmaceutical industries [124]. 
However, such substitutions may be controlled over the reaction conditions applied [68, 113], as is 
shown here. 
2.5.2.1 Alkylation 
The alkylation is one of the most frequent modifications of CS. Alkylation reactions occur through 
the grafting of alkyl chains in the structure of the CS. In other words, alkyl CS is obtained by the 
introduction of alkyl groups on the amine groups of CS by reductive amination of CS [125]. Generally, 
this substitution reaction is carried out in heterogeneous conditions and owing to the semi-crystalline 
character of CS, amorphous regions will be more accessible than ordered ones, giving rise to 
substituted products displaying block distribution patterns.  
The hydrophobic character of alkylated CS is dependent on the length of the chains,  i.e., the 
longer the alkyl chains, the higher the polymer hydrophobicity [126]. Additionally, the higher the 
average degree of substitution (DS), the more hydrophobic will be the modified CS. 
Desbrieres et al., [125], developed a procedure to obtain alkylated derivatives of CS from its 
swollen structure and modified after precipitation by neutralization, which improves the accessibility 
to the reactive sites. Generally, aldehydes and ketones are employed as alkylating agents and the 
Schiff bases resulting from reaction with CS are converted to N-alkyl CS derivatives by reduction with 
sodium borohydride (NaBH4) or sodium cyanoborohydride (NaBH3CN) (Figure 2.13), the reaction 
efficiency depending on the choice of the reducing agent [68]. Indeed, NaBH3CN is commonly used 
because it is more reactive and selective, but it is highly toxic [68].  
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Figure 2.13 - Reaction scheme to obtain N-alkyl derivatives of chitosan. 
 
CS modifications can dramatically alter its properties, therefore, it is necessary to characterize 
the properties and medical safety of these new derivatives [127]. Indeed, the presence of hydrophobic 
interactions between the alkyl chains improves the properties of modified CSs: the C12 is the minimum 
length of the alkyl chain for the hydrophobic behavior be effective; the solutions of such CS derivatives 
are usually non-Newtonian, mainly when the length of alkyl chains increases; also de C12 alkyl chain 
length proved to be more efficient to improve film formation and mechanical properties; the 
efficiency of this modification increases with increasing DS [126]. 
Apart from their properties, alkyl chitosan derivatives have been widely used in drug delivery. In 
Section 2.5.3, examples are given of this modification.  
2.5.2.2 Acylation 
The addition of hydrophobic groups is also carried out by acylation reactions. Acylated CS was 
proposed as a drug carrier for drug delivery, essentially due to its hydrophobic association that 
promotes self-assembly of nanoparticles or micelles. The advantage of the acylation of CS over its 
alkylation occurs because the acylation allows the introduction of new groups in sites C2-amine, C3-
hydroxyl and C6-hydroxyl [68]. In the case of O-acylation, the presence of the ester bond in the 
structure of the resulting CS derivative permits its degradation by the action of lipase enzymes, 
making it a biodegradable polymer [68].  
The acylation of CS makes possible its solubilization in organic solvents due to the introduction of 
hydrophobic groups in the polymer. However, the solubility of acylated CS in water depends on the 
acyl chain length and on DS [68, 128]. This means that short acyl chains and relatively low DS result 
in water soluble CS derivatives but increasing the DS will dramatically decrease the water solubility. 
2.5.2.2.1 N-acylation 
The N-acylation of CS may be achieved by activation of carboxylic acids through reaction with 
carbodiimides as well as by using reactive carboxylic acid derivatives, such as anhydrides and acyl 
chlorides. 
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Carbodiimide reactions are carried out by activation of carboxylic acids in the presence of 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide (EDC). This reaction gives rise to the intermediate O-
acylisourea, which is capable of undergoing nucleophilic attack of the primary amine groups, such as 
those present in GlcN units of CS [68]. The primary amine connects to the carboxyl group through an 
amide bond and release the by-product urea derivative, isourea. The reaction scheme is shown in 
Figure 2.14.  
In carbodiimide reactions it has been commonly used N-hydroxisuccimide (NHS) or its water-
soluble sulfo-NHS with the EDC. Adding this, the efficiency of the reaction is improved through the 
formation of an amine-reactive intermediate that is more stable than the O-acylisourea. The reaction 
scheme addition of NHS is shown in Figure 2.15. 
Lee et al. [129], carried out the CS modification with EDC and it is possible to verify that with an 
increase in the amount of deoxycholic acid and EDC there is an increase of the DS. However, the DS 
ranges from 2.8 to 5.1 per 100 anhydroglucosamine units of CS, concluding that the limited solubility 
of deoxycholic acid in the reaction medium affected the achievement of derivatives with higher DS. 
The same was observed in the reaction with linoleic acid, the resulting DS attaining only 1.8% [130].  
Other methodology for obtaining acylated CS is by reaction with anhydrides, which results in 
selective N-substitution. This reaction can be carried out in homogeneous [131] or heterogeneous 
[132] conditions. The reaction scheme is shown in Figure 2.16.  
 
Figure 2.14 - Acylation modification by carbodiimide reaction. 
 
Figure 2.15 - Acylation synthesis from the use of EDC and NHS. 
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2.5.2.2.2 O-acylation 
The reactions presented above aim to produce the N-acylation of CS. However, the O-acylation 
reactions may also occur, as many of these reactions are not fully selective for amine groups. Thus, 
the preparation of derivatives with well-defined structures can be achieved through the control of 
reaction conditions, allowing the preparation of advanced functional materials from CS. 
Since amine groups are stronger nucleophiles as compared to primary and secondary hydroxyl 
groups, the preparation of N-phthaloyl CS derivative is a promising advance as besides being a 
regioselective reaction, it is easily carried out under mild conditions. The phthaloyl group is commonly 
used as protector of amine groups and after protection; O-substitution reactions are carried out. 
Finally, the phthaloyl group is removed by reaction with hydrazine, regenerating the amine groups 
[133]. Figure 2.17 shows the phthaloyl protecting group and reaction of O-acylation. 
In spite of the reactions with phthaloyl be effective, this approach needs several steps, including 
the protection and deprotection of the amine groups, favoring the occurrence of side-reactions as 
well as low reaction yield. Therefore, a new method was developed using methanesulfonic acid 
(CH3SO3H) to protect the amine groups, allowing the occurrence of selective O-acylation by reaction 
with acyl chlorides [68]. As a strong acid, methanesulfonic acid is able to protonate the amine groups 
through the formation of salts, resulting in the substitution preferentially on the hydroxyl groups of 
CS, as shown in Figure 2.18.  
 
 
Figure 2.16 - N-acyl chitosan reaction by anhydrides.  
 
Figure 2.17 - Reaction of protection through the phthaloyl group. 
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2.5.3 Chitosan derivatives in drug delivery of anticancer drugs 
Currently, new chemical formulations for drugs are developed, but the low solubility in aqueous 
media and unacceptable levels of toxicity for drugs or excipients in the formulation has been a 
limitation. The first formulations developed had in its composition solubilizing agents [134]. However, 
it exhibited secondary effects. Thereby, the advance of studies in this area led to the development 
of new types of formulations, such as systems based in nanoparticles and micelles, with the aim of 
avoid the use of such solubilizing agents [135]. Polymer-based micelles and nanoparticles produced 
from CS derivatives have been considered as promising carriers for bioactive molecules. Accordingly, 
some applications are presented below for these amphiphilic derivatives of CS in drug delivery 
systems.  
Amphiphilic CS derivatives have already proven to be excellent systems for drug delivery when 
loaded with anticancer agents such as PTX, camptothecin or DOX.  
The derivatives N-succinyl-N-octyl chitosan (SOC) were synthesized by N-substitution reaction in 
the presence of sodium borohydride. The three derivatives obtained had DS ranging between 28.6-
52.5% and CMC values were 3.1×10-5, 2.4×10-5 and 5.9×10-6 g/mL [14]. The CMC decreases with 
increasing DS of octyl content. The encapsulation of doxorubicin DOX was achieved by dialysis and 
was affected by the amount of octyl groups, increasing in function of DS [14]. Additionally, the 
average size of these micelles was dependent on the amount of the octyl chains, ranging between 
100-200 nm. These results showed a sustained release pattern, also dependent on the amount of the 
octyl chains and drug loading (DL) content: the higher drug content had the slower drug release [14]. 
Additionally, these polymer-based micelles exhibit more toxicity than the free drug, which may be 
useful as a carrier DOX drug in anticancer treatment.  
Zhang et al. [82], developed N-octyl-N-trimethyl chitosan derivatives (OTMCS) by introducing the 
octyl group in chitosan backbone followed by N-methylation, resulting in a derivative possessing 
average degree of substitution of 8% and 54% for octyl and trimethyl substituents, respectively [82]. 
This new derivative, OTMCS, can form micelles by self-assembly and is capable of encapsulate 
hydrophobic drugs such 10-hydroxycamptothecin, enhancing their solubility in aqueous media. The 
results showed an average particle size ranging between 24-278 nm and DL content between 4.1-32%, 
depending of the DS [82]. Additionally, the results showed a sustained-release behavior of the drug 
and good stability of the system. Concluding, these micelles could be promising carriers for 
hydrophobic drugs, improving their solubility, stability and release.  
In another example from the same author, N-octyl-O-sulfate chitosan (NOCS) was prepared via 
reductive amination. NOCS micelles have been used to study the release of PTX. The loading of PTX 
and formation of micelles occur via dialysis using ethanol and water as solvent selected [55]. The 
solvents used to dissolve both, the polymer and the drug, and the feed weight ratio of PTX to the 
 
Figure 2.18 - Reaction of O-substitution through the protection of amine groups with CH3SO3H. 
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polymer, significantly affected the encapsulation efficiency (EE), ranging between 37.6-59.1% [55]. 
However, the highest EE was observed when the feed weight ratio of PTX to the polymer was 1:1.5–
1:1.7 [55]. The PTX-loaded micelles presented sizes around 250 nm and spherical shape without 
aggregation with high PTX loading, about 25% [55], which still is a promise nanocarrier for hydrophobic 
drugs. Therefore, the authors used these same micelles for in vivo studies [136]. The biodistribution 
study revealed that the drug retention was higher in the liver, followed by kidney and lung 15 minutes 
after administration. However, after 8 hours, the concentration of PTX became higher in the spleen, 
liver, lung and kidney [136]. Still, the brain and spinal cord were exposed to low concentrations of 
PTX. The antitumor efficacy in different animal tumor models of PTX-loaded micelles seems to be 
more efficient in inhibition of tumor growth at certain concentrations than when used Taxol®. 
However, at the concentration of 10 mg/kg both have similar behaviors. Regarding toxicity, only the 
Taxol® shows toxic effects [136]. These results indicate that the use of NOCS loaded with PTX is more 
beneficial than the conventional system containing Cremophor EL, overcoming the limitations and 
providing the necessary therapeutic efficacy. 
The galactosylated O-carboxymethyl chitosan-graft-stearic acid (Gal-OCMC-g-SA) was synthesized 
by coupling the carboxyl group of stearic acid (SA) with the amine group of O-carboxymethylchitosan 
(OCMC) in the presence of EDC and NHS [83]. This derivative was synthesized for liver targeting 
delivery of DOX and has a DS of stearic groups ranging from 4.6% to 12.6% and galactose DS from 
13.1%. Also, the particle size and polydispersity index decreased with increasing DS, through a non-
linear relation [83]. These results indicated that the nanoparticles with spherical shape had a DL 
content around 13% and an EE around 77%, depending on the DS. The in vitro release studies, showed 
that the DOX loaded Gal-OCMC-g-SA nanoparticles had a pH-dependent release of DOX, which may be 
beneficial to the accumulation of drug in tumor tissues [83].  Additionally, the hemolysis test showed 
good safety of these micelles in blood-contacting applications, which indicate that material as 
potential application for the treatment of cancer, specially, for liver targeting. 
Balan et al. [13], used different amounts of hydrophobic groups of palmitoyl chloride (PC) to 
prepare, through a nucleophilic acyl substitution reaction, a novel amphiphilic derivative, where free 
amine groups of chitosan are able to react with the carboxyl groups of acyl halides to form an amide 
bond. N-palmitoyl CS and magnetite were used to load DOX into magnetic nanocapsules, using a 
double emulsion method. Magnetic nanocapsules exhibited suitable magnetic saturation, 
superparamagnetic behavior and good ability to incorporate a chemotherapeutic agent [13], 
properties which can be exploited in many different areas of biomedicine. These magnetic 
nanocapsules showed a DS directly related with molar ratio. At 1/0.5, 1/1 and 1/2 chitosan/PC molar 
ratio, the DS (%) was 7.69±0.42, 12.35±1.60 and 25.57±2.33, respectively. Consequently, due to the 
fact that part of amine groups have been substituted, the zeta potential decreases because there are 
fewer  amines [13]. These systems showed a narrow size distribution of 215±23.33 nm, EE of 73% and 
DL of 1.54%. Also, in vitro drug release exhibited a biphasic drug release with an initial burst effect 
in the first 6 hours, followed by a constant release up to 6 days [13]. The cytotoxicity studies revealed 
that the empty magnetic nanocapsules do not have cytotoxicity at the highest concentration tested, 
which is a good evidence to be used as drug delivery system. 
Oleoyl chloride has been used to synthesize oleoyl-chitosan (OCH) and this CS derivative was 
applied to load nanoparticles with DOX. In this research, the DS of the OCH derivative was 11% and 
the diameters of empty and loaded with DOX nanoparticles were 255.3 nm and 315.2 nm, respectively 
[15]. The results showed that these nanoparticles had EE around 53% and the drug release was fast 
and complete at pH 3.8, whereas at pH 7.4 there was a sustained release after a burst release. 
23 Literature Review 
 
 
Additionally, the toxicity of OCH nanoparticles was investigated by MTT assay and the results showed 
low toxicity of the material at all concentrations as well as the hemolysis test showed a non-toxic 
level. Finally, the inhibition of DOX-OCH nanoparticles to human cancer cells in vitro have shown 
inhibitory effects on the growth of four cancer cell lines (A549, Bel-7402, HeLa, and SGC-7901) at 
most concentration levels (1000 μg/mL) than that of DOX. [15].  
Gu et al. [84], produced chitosan-graft-poly(ε-caprolactone) (CS-g-PCL) through acylation 
modification to encapsulate 5-Fu as anticancer system. The polymer-based micelles prepared had a 
particle size in the range 61.4-108.6 nm depending on the DS with spherical shape after introduction 
the drug and, the EE was above 90% for a DL content of 14.8% [84]. The in vitro drug release of 5-Fu 
loaded micelles occurred in a sustained manner and had the controlled release behavior. Additionally, 
the cytotoxicity test made by MTT assay showed no cytotoxicity against A549 and MCF-7 cells for 
empty micelles and the loaded micelles as well. However, the latest present lower toxicity when 
compared with free drug [84]. 
All of the examples presented above appear to be quite promising systems for loading and delivery 
of hydrophobic drugs, particularly anticancer drugs. There is still much research to be done until it 
can take each of these systems in the treatment of human cancer. 
 
Table 2.2 - Overview of amphiphilic chitosan derivatives used to encapsulate anticancer drugs. 
Chitosan derivative Modification System Active agent Reference 
SOC Alkylation Micelles Doxorubicin [14] 
OTMCS Alkylation Micelles 10-hydroxycamptothecin [82] 
NOCS Alkylation Micelles Paclitaxel [55] 
Gal-OCMC-g-SA Acylation Nanoparticles Doxorubicin [83] 
N-palmitoyl chitosan Acylation Nanocapsules Doxorubicin [13] 
OCH Acylation Nanoparticles Doxorubicin [15] 
CS-g-PCL Acylation Micelles 5-fluorouracil [84] 
2.6 Polycaprolactone 
Polycaprolactone (PCL) was extensively used in the biomaterial’s field and a number of drug 
delivery devices during the resorbable-polymer-boom of the 1970s and 1980s increased [3]. In recent 
years, PCL, that is prepared by ring-opening polymerization (ROP) of ε-caprolactone (ε-CL) [137], has 
been used again due to their rheological, viscoelastic properties, excellent mechanical strength and 
nontoxicity superior to many of their counterparts of aliphatic polyesters [138] (see Table 2.3), which 
makes it easy to manufacture and to handle for a wide variety of implants and devices [3, 139, 140]. 
It is known to their biocompatibility and biodegradability, which make it a useful material in 
resorbable sutures, scaffolds in tissue engineering and recently in bone graft substitutes [141-144]. 
However, the drug delivery field has been extensively explored. Unlike most aliphatic polyesters, PCL 
is always in a rubbery state at RT which makes it highly permeable for many therapeutic drugs [66, 
67]. 
PCL is a hydrophobic and semi-crystalline polymer approved by the U. S. Food and Drug 
Administration (FDA) [3], having a glass transition temperature (Tg) of -60 ºC and it is crystallinity 
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tends to decrease with the increasing of Mw [145]. The good solubility of PCL, its a low melting point 
(Tm) (59-64 ºC) and exceptional blend-compatibility has stimulated extensive research into it is a 
potential application in the biomedical field [145]. It has a thermal decomposition temperature (Td) 
of 350 ºC, which is much higher than that of other aliphatic polyesters (235-255 ºC) [138, 146]. These 
and other characteristics are summarized in Table 2.3.  
 
Table 2.3 - Summary of the polycaprolactone features. 
Feature  Reference 
Crystallinity (%) 67 % [145] 
Glass transition temperature (Tg) Tg= -60 ºC [67, 145] 
Melting Point (Tm) Tm= 59 ºC to 65 ºC [67, 145] 
Thermal decomposition temperature (Td) Td= 350 ºC [138, 146] 
Young's modulus (MPa) 197 [67, 145] 
Water permeability at 25 ºC (g/m2/day) 177 [145] 
 
This polymer is soluble in chloroform, dichloromethane, benzene, toluene and cyclohexanone at 
RT [147, 148]. By contrast he has a low solubility in acetone, 2-butanone, ethyl acetate, DMF and 
acetonitrile and is insoluble in alcohol, petroleum ether and diethyl ether [147, 148]. 
As already mentioned, PCL can be prepared by ROP of the cyclic ε-CL monomer [149] (Figure 
2.19). The ε-CL consists of 5 nonpolar methylene groups and single relatively polar ester group which 
gives it unique properties outlined above [66].  The synthesis of PCL by ROP goes according to four 
different mechanisms: cationic, anionic, activated monomers and coordination of polymerization of 
the opening of ε-CL ring [67].  
 Figure 2.19 - Synthesis of polycaprolactone from ε-caprolactone by ring-opening polymerization. 
 PCL degrades more slowly than polyglycolide and poly D,L-lactide, and for this reason, is used in 
drug-delivery devices that remain in the body for over a year [3]. Furthermore, the fact of being 
biocompatible and hydrophobic makes PCL a polymer of excellence. 
 A promise to this material is the development and synthesis of PCL-based amphiphilic block 
copolymers [150]. Since the administration of therapeutic compounds may be hampered by its low 
solubility in water, this problem can be solved when combined with another biomaterial, for example, 
the CS. In this case, the combination of the hydrophobic PCL with the hydrophilic CS lead to self-
assembly micelles. These, in turn, are capable of increasing the solubility of hydrophobic molecules, 
as already mention above. 
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2.7 Chitosan-grafted-polycaprolactone (CS-g-PCL) 
Over the past few years, research into biomaterials for drug delivery has been long. Particularly, 
polymers for drug delivery has been explored because the improvement solubility of therapeutic 
molecules. As PCL degrades more slowly than other aliphatic polyesters, by having a rubber behavior 
at RT, and due to other properties already discussed above, it is one of the major polymers chosen 
for drug delivery. Thus, synthetize a hybrid biomaterial by grafting CS and PCL is a big deal because 
their problems of solubility well known. 
Besides overcome the solubility problems through the PCL graft CS [151], hydrophilicity of CS 
enhances the wettability and permeability of PCL by accelerating the hydrolytic degradation of PCL 
[137]. Moreover, the distribution of the hydrophobic chains of PCL by the hydrophilic phase of CS, 
promotes cell attachment and adsorption of proteins [152].  
Several methods of synthesis of these polymers have been performed. However, combining CS 
and PCL by grafting is considered the most effective method to form a biofunctional biomaterial by 
the combination of the excellent properties of both polymers [153]. There are several grafting 
methods to produce this excellent biomaterial. For example, Cai et al., [154] used stoichiometric 
sodium dodecyl sulfate-CS complex as an intermediate and the grafting level of PCL could be 
modulated by adjusting the PCL and sulfate-CS complex weight ratio. Already Yu et al., [151] used N-
phthaloyl CS as an intermediate to synthetize CS-g-PCL. This reaction is called protection-grafting-
deprotection route. In this situation, the amino groups of CS are protected and just the hydroxyl 
groups at C-3 and C-6 are remained as active initiating points for grafting. After that, the phthaloyl 
groups are deprotected to regenerate free amino groups, as already described above. 
On the other hand, ROP of ε-CL through CS is a method that allows a high grafting level of PCL 
polymer [155]. Usually, this reaction is developed with 4-dimethylamino-pyridine as a catalyst and 
water as a swelling agent [84, 156] or methanesulfonic acid as solvent and catalyst [5, 155] or using 
stannous octoate as a catalyst [153]. 
Another approach is also possible. To synthesize CS-g-PCL, Liu et al., [157] used ROP of ε-CL onto 
phthaloyl-protected CS in the presence of tin (II) 2-ethylhexanoate catalyst via a protection-grafting-
deprotection route in the presence of toluene [157]. 
In this dissertation, to reach CS-g-PCL a carbodiimide reaction by amidation was employed. From 
PCL modified with a terminal carboxyl group it is possible graft PCL onto CS backbone using amine 
coupling agent DCC/NHS at an alkaline pH, reacting the carboxyl end groups of PCL with the amine 
groups of CS. The product of this reaction, CS-g-PCL, is a CS amphiphilic derivative modified by N-
acylation (see Section 2.5.2.2.1). PCL with a terminal carboxyl group is activated with DCC which is 
then stabilized with NHS, forming PCL succinimide ester (PCL-NHS). After removing the insoluble by-
product, dicyclohexylurea, PCL-NHS activated is added to the CS solution is comprised of acetic acid 
and sodium hydroxide to a pH of 7-8. The reaction between two polymers continued at 50 ºC for 24 
h. 
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Chapter 3  
Material and Methods 
3.1 Chemical material 
To assess the degree of acetylation (DA) and de molecular weight (Mw) of chitosan (CS, Sigma 
Aldrich), N-acetyl-D-glucosamine from Sigma Aldrich was used. Acetic acid and sodium acetate were 
from Panreac. 
Polycaprolactone (PCL) was purchased from Polyscitech (PCL, 1-5 KDa). The carboxylic end groups 
of the PCL were activated by N,N’-Dicyclohexylcarbodiimide (DCC, Alfa Aesar) and N-
Hydroxysuccinimide (NHS, Sigma Aldrich) for direct conjugation with CS by amidation reaction. 
Dichloromethane (DCM, Merck Millipore) and dimethylformamide (DMF, Merck Millipore) was used to 
solubilize PCL.  
Paclitaxel (PTX) was kindly provided by Indena SpA – Milano, and the centrifugal filters (Amicon® 
Ultra-15, 100 kDa) were used to separate the unencapsulated drug of the micelles. To perform the in 
vitro release study was used 10 KDa cut-off dialysis membrane (Thermo Scientific), phosphate-
buffered saline (PBS) and Tween®-80 (Sigma Aldrich). 
3.2 Cell culturing 
Colorectal cancer cell lines, C2BBe1 Clone of Caco-2 was obtained from American Type Culture 
Collection (ATCC, USA), and HT29-MTX cell line was kindly provided by Dr. T. Lesuffleur (INSERMU178, 
Villejuif, France). Dulbecco's modified Eagle medium (DMEM, Lonza), was supplemented with 10% 
(v/v) fetal bovine serum (FBS, Merck Millipore), 1% (v/v) penicillin (100 U/mL, Merck Millipore), 
streptomycin (100 µg/mL, Merck Millipore) and 1% (v/v) non-essential amino acids (NEAA, Merck 
Millipore). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and dimethyl 
sulfoxide (DMSO) were obtained from Sigma Aldrich, Triton X-100 1% from Spi-Chem, and culture 
flasks, 96-well tissue culture plates and Transwell® plates were purchased from Corning Inc., USA. 
The plates were read in microplate spectrophotometer (Biotek Synergy 2, USA) and cells were 
maintained in an incubator (ESCO CelCulture® CO2 Incubator, Singapore) at 37 ºC temperature and 
5% CO2 in a water saturated atmosphere. 
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3.3 Methods 
3.3.1 Degree of acetylation 
The spectrophotometer UV/Vis spectrometer (UNICAM) used to determine the DA of CS was 
utilized in the spectrum range of 190 to 240 nm. Three solutions of acetic acid at of 0.01, 0.02 and 
0.03 M were prepared and recorded the first derivative spectra, against water. The superposition of 
the three spectra shows the zero crossing point (H, at 203 nm), that is when all the acetic acid spectra 
share a common point. The zero crossing point is close to the N-acetyl-D-glucosamine maximum on 
the wavelength axis what makes the N-acetyl-D-glucosamine determination independent of the acetic 
acid concentration in the concentration [158]. 
Then were prepared 5 references of N-acetyl-D-glucosamine in the range 0.5 – 3.5 mg (0.5 mg, 1 
mg, 1.5 mg, 2.5 mg and 3.5 mg) in 100 mL of acetic acid 0.01 M and record the spectra as before. For 
the spectrum of CS was dissolved 500 mg in 50 mL of 0.1 M acetic acid and then dilute to 500 mL with 
water.  
The determination of DA of chitosan by 1H NMR were also performed. Approximately, 6 mg of CS 
was dissolved in 1 mL of hydrochloric acid/deuterium oxide 1% (HCl/D2O, v/v) under constant 
magnetic stirring for 24 hours at RT. The resulting solution was transferred into quartz tube (Noreli 
507-HP) and the conditions employed in spectrum acquisition were: a) water suppression pulse 
sequence to 1-1 with an interval of 3 s between the pulses suppression; b) accumulation of 32 scans; 
c) 7s relaxation interval; d) 80 ºC; e) spectral window of 10.0 ppm.  
This method consists in using the area under the peak at 2 ppm region assigned to the methyl of 
hydrogen nuclei of the acetamide group (ACH3) and the area of peak attributed to the proton attached 
to 2-carbon of the glucosamine ring (AH2-H6) as it has already been described [159]. The areas were 
obtained from the ACD/ChemSketch software. Then, the DA is obtained from the following equation: 
 
                                          %𝐷𝐴 =
𝐴(𝐶𝐻3)
3
𝐴(𝐻2−6)
6
× 100                (3.1) 
3.3.2 Molecular weight 
To determine the Mw was used the Ubbelohde capillary viscometer (Kapillar-Viskosimeter, 
Schott). First, a solution of acetic acid 0.5 M in 500 mL of distilled water was prepared. Then, CS was 
dissolved in acetic acid 0.5 M/sodium acetate 0.2 M at 3 different concentrations (0.01 g/dL, 0.02 
g/dL and 0.04 g/dL). 
The viscometer was immersed in a constant temperature bath at 25 ± 0.1°C. The flow time (𝑡) 
was recorded and this procedure was repeated five times for each concentration. The average of Mw 
was obtained from Mark-Houwink equation: η = K𝑀𝑣
𝑎, where [η] is the intrinsic viscosity, Mv is the 
average of Mw of the solution and K and a are the Mark-Houwink constants specific for a given polymer 
[160]. 
To reach the intrinsic viscosity, the following equations were calculated: 
𝜂𝑟 =
𝑡
𝑡0
      (3.2) 
𝜂𝑠𝑝 = 𝜂𝑟 − 1      (3.3) 
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𝜂𝑠𝑝 𝑟𝑒𝑑 =
𝜂𝑠𝑝
𝐶
      (3.4) 
𝜂𝑖𝑛 =
ln 𝜂𝑟
𝐶
      (3.5) 
[𝜂] =
𝜂𝑠𝑝
𝐶 𝐶=0
      (3.6) 
 
where, 𝜂𝑟 is the relative viscosity, 𝑡 is the solution flow time in the viscometer; 𝑡0 is the time flow of 
the pure solvent in the viscometer; 𝜂𝑠𝑝 is the specific viscosity; 𝜂𝑠𝑝 𝑟𝑒𝑑 is the reduced specific viscosity, 
also known by the Huggins equation; 𝜂𝑖𝑛 is the inherent viscosity, also known by the Kraemer equation; 
𝐶 is the concentration of polymer in g/dL; [𝜂] is the intrinsic viscosity in dL/g and is calculated 
extrapolating (𝐶 = 0) the linear regression obtained by plotting 
𝜂𝑠𝑝
𝐶
 against C, according to Huggins 
equation. 
3.3.3 Synthesis of chitosan-grafted-polycaprolactone  
 The synthesis of chitosan-grafted-polycaprolactone (CS-g-PCL) was carried out based on the work 
done by Elkhooly et al. [161]. Briefly, 2% (w/v) chitosan solution was prepared by dissolving in 2% 
(v/v) acetic acid in a glass beaker with moderate stirring until the complete dissolution of CS. The pH 
of the supernatant was adjusted with 3M NaOH to 7-8. The deprotonation of CS amine groups is 
essential step to improve the efficiency of conjugation, because of the activated succinimide ester 
reacts with primary amines at physiologic to slightly alkaline conditions (pH 7.2 - 9). PCL (1 g) was 
dissolved in 50 mL of 1:1 (v/v) DMF/DCM. After complete dissolution of PCL, 2.5 mmol of DCC and 2.5 
mmol NHS was added to the solution. The activation reaction of the carboxyl group of the PCL (which 
will react with the amine groups of CS) through NHS using DCC as a catalyst was carried out for 12 h 
at RT. The insoluble by-product of this reaction, dicyclohexylurea, was removed by centrifugation for 
20 minutes at 15 ºC and 4300 rpm (Thermo Scientific Heraeus Megafuge 1.0R). The obtained solution 
was further filtered under vacuum. To remove the excess of reagent DCC/NHS, the activated PCL 
solution was dialyzed against 10 fold volume of DMF/DCM using 10 KDa cut-off dialysis membrane 
(Thermo Scientific) for 2 days with two changes of volumes. Finally, 12.5 mL of activated PCL (PCL-
NHS) solution was added into 50 mL of CS solution (pH= 7-8) and stirred for 24 h at 50 ºC. 
Figure 3.1 - Synthesis scheme the reaction of chitosan with polycaprolactone through chitosan modification by 
N-acylation. 
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3.3.4 Characterization of chitosan-grafted-polycaprolactone  
Nuclear magnetic resonance (NMR, Bruker Avance III 400) was performed in order to confirm the 
formation of the new copolymer. Approximately, 6 mg of samples were dissolved in 1 mL of HCl/D2O 
1% (v/v) for chitosan, CDCl3 for polycaprolactone and HCl/D2O 1% (v/v) for graftcopolymer under 
constant magnetic stirring for 24 hours at RT. The resulting solution was transferred into quartz tube 
(Noreli 507-HP) and the conditions employed in spectrum acquisition were: a) water suppression pulse 
sequence to 1-1 with an interval of 3 s between the pulses suppression; b) accumulation of 32 scans; 
c) 7s relaxation interval; d) 80 ºC; e) spectral window of 10.0 ppm. 
Attenuated total reflection Fourier transforms infrared spectroscopy (ATR-FTIR) spectra of each 
sample were generated by ABB MB3000 FTIR spectrometer from ABB (Zurich, Switzerland) equipped 
with a MIRacle single reflection attenuated total reflectance (ATR) accessory from PIKE Technologies 
(Madison, WI, USA). All spectra were collected with 256 scans and a 4 cm-1 resolution in the region of 
4000-600 cm-1.  
Contact angle of the copolymer and the commercial chitosan were measured on an optical contact 
angle measuring device (OCA15, Dataphysics Instruments Co. Ltd, German) to determine the 
hydrophilicity/hydrophobicity of the new polymer obtained. For this test, 200 mg of each sample was 
subjected to vacuum during 2 minutes followed by 8 tons for 30 seconds, in order to form a tablet. 
For the drop, 4 µL of distilled water are released from a needle (0.50 mm) falling on the tablet. 
Contact angles are measured using the Laplace-Young method with brightness of 96 and contrast of 
511 at 15 seconds after the fall of the drop, focused by a high performance CCD camera. 
The critical micelle concentration (CMC) of CS-g-PCL was determined by a conductimetric titration 
(Consort C863, Spain) carried out at 25 ºC. The procedure consists of measuring the conductivity of 
various copolymer concentrations (1 mg/mL - 1 × 10−6 mg/mL). Then, the concentration values used 
are used in logarithmic values with the respective values previously found and, the CMC was obtained 
by the meeting of two lines of the graph of conductivity against concentration.  
3.3.5 Preparation of paclitaxel-loaded chitosan-grafted-
polycaprolactone micelles 
The paclitaxel-loaded chitosan-grafted-polycaprolactone (PTX-CS-g-PCL) micelles were prepared 
by evaporation method. First, 5 mg of copolymer was dissolved in 5 mL of acetic acid 0.1M and DMF 
(1:1) (v/v). Then, to the homogeneous mixture was added dropwise 250 µL, 125 µL, 50 µL or 25 µL of 
PTX solution at concentration of 1 mg/mL (for different PTX loading), dissolved in 70% ethanol, which 
corresponds to a drug mass compared to the mass of copolymer of 5.0%, 2.5%, 1.0% and 0.5%, 
respectively. The mixture was allowed under stirring for 4 h to evaporate the solvent. After 4 h, the 
solution was sonicated for 5 minutes in iced bath. Then, the solutions was centrifuged through 
Amicon® Ultra-15 100 kDa at 5000 rpm during 10 minutes to remove the unencapsulated drug. After 
filtration, PTX-CS-g-PCL polymeric micelles were collected. In Figure 3.2 is possible observe a 
schematic representation of the method used to produce PTX-CS-g-PCL micelles.  
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Figure 3.2 – Schematic representation of the method used to prepare PTX loaded CS-g-PCL micelles. 
3.3.6 Characterization of paclitaxel-loaded chitosan-grafted-
polycaprolactone micelles 
The average diameter, polydispersity index and surface charge were determined by dynamic light 
scattering (DLS) and electrophoretic light scattering (ELS) (ZetaSizer Nano ZS, Malver, UK), 
respectively. All measurements were performed with three independent batches of micelles, with 
three runs each.   
The PTX encapsulation efficiency (EE) and drug loading (DL) of micelles were assessed indirectly 
by assaying the amount of drug recovered in supernatants resulting from centrifugation by high 
performance liquid chromatography (HPLC, Merck-Hitachi 7000). The HPLC analysis of PTX samples 
was achieved on a LiChrospher® 100 RP-18 (5 µm) (Merck Millipore) with guard column with a mobile 
phase consisting of methanol and water (65:35, v/v) at a flow rate of 1.0 mL/min. The sample 
injection volume was 20 µL, and the absorbance wavelength was set at 227 nm in an UV detector. 
The EE and DL was calculated using the following formula, respectively: 
 
       𝐸𝐸% =
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑝𝑎𝑐𝑙𝑖𝑡𝑎𝑥𝑒𝑙−𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑝𝑎𝑐𝑙𝑖𝑡𝑎𝑥𝑒𝑙
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑝𝑎𝑐𝑙𝑖𝑡𝑎𝑥𝑒𝑙
× 100     (3.7) 
 
         𝐷𝐿% =
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑝𝑎𝑐𝑙𝑖𝑡𝑎𝑥𝑒𝑙−𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑝𝑎𝑐𝑙𝑖𝑡𝑎𝑥𝑒𝑙
𝑚𝑖𝑐𝑒𝑙𝑙𝑒𝑠 𝑤𝑒𝑖𝑔ℎ𝑡
× 100   (3.8) 
The morphological features of the micelles were observed by transmission electron microscope 
(TEM). Samples were prepared by placing 10 μL of micellar solution obtained after centrifugation on 
300 mesh nickel grids, and after 2 minutes the excess of suspension was removed with filter paper 
and, examined under a JEOL JEM 1400 TEM (Tokyo, Japan). Images were digitally recorded using a 
Gatan SC 1100 ORIUS CCD camera (Warrendale, PA, USA).  
3.3.7 In vitro paclitaxel release studies 
The in vitro release profiles of free PTX and the PTX-CS-g-PCL micelles were studied by dialyzing 
the drug-loaded micellar solution against 40 mL of PBS (pH 7.4, 0.1% (w/v) Tween®-80). From the 
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micellar solution obtained, 2.5 mL were placed in a dialysis membrane (10 KDa cut-off, Thermo 
Scientific). The membrane was then immerged into the release medium. Each sample was gently 
agitated at 100 rpm at 37°C (IKA KS 4000i Control). At predetermined time intervals (0.25, 0.5, 075, 
1, 2, 4, 6 and 8 h), 2 mL of release medium was removed, and the same volume of medium was 
refreshed. The amount of PTX released was determined by HPLC analysis, as described below.  
In order to compare the release profile of the PTX encapsulated in micelles with the free PTX, 
156 µL of PTX at concentration of 1 mg/mL was added at release medium to perform a volume of 2.5 
mL. Then, this solution was placed in a dialysis bag was conducted under the same conditions 
described. The release experiments were conducted in triplicate and the mean was calculated. 
Tween®-80 was included in the release medium to increase the solubility of PTX as well as to 
prevent binding of the PTX to the dialysis membrane, maintaining the sink conditions [162]. One 
requirement for achieving a suitable drug dissolution test is to use a sufficient volume of dissolution 
medium or release medium that should be able to dissolve the expected amount of drug released. 
This ability to dissolve the expected amount of drug is known as a sink conditions. 
3.3.8 Cytotoxicity studies 
Potential cytotoxicity of CS, PCL, empty micelles, free PTX and PTX-CS-g-PCL micelles was tested 
against Caco-2 (C2BBe1 clone) and HT29-MTX cells, colorectal cancer cells, using MTT reagent. Caco-
2 (passage 51-74) and HT29-MTX (passage 41-63) cells grew separately in culture flasks in a complete 
medium consisting of DMEM supplemented with 10% (v/v) FBS, 1% (v/v) L-glutamine, 1% (v/v) NEAA, 
and 1% (v/v) antibiotic-antimitotic mixture (final concentration of 100 U/ml Penicillin and 100 U/ml 
Streptomycin). The culture medium was replaced every other day. Cells were seeded (200 μL) into 
wells of 96-well tissue culture test plates with 1×104 cells/well for HT29-MTX cell line and 2×104 
cells/well for Caco-2 and incubated at 37ºC in a 5% CO2 air atmosphere for 24 hours. Then, medium 
was removed and cells are washed twice with 200 μL of PBS. Then was replaced fresh warm medium 
(200 μL) with different concentrations (0.01 - 0.1 – 1 – 10 – 100 – 1000 μg/mL) of CS, PCL, empty 
micelles, PTX-CS-g-PCL micelles and free PTX (the latter two were not performed cytotoxicity at the 
two highest concentrations). A negative control (Triton X-100 1%) and positive control (medium with 
cell incubation) was included. After 4 h and 24 h of incubation at 37 ºC in 5% CO2 atmosphere, the 
medium was discarded and cells were washed twice with 200 µL of PBS. Finally, was added 200 μL of 
MTT solution per well (final concentration of 0.5 mg/mL) and was incubated for 4 h in dark. After 4 
h, was removed and discard the MTT solution, and was added 200 μL of DMSO to dissolve the MTT 
formazan crystals. The plates were placed in orbital shaker for 15 min in the dark, at RT and the 
absorbance was measured using a microplate spectrophotometer at 570 nm and 630 nm. The results 
was analysed according to the following equation:  
𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =
𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑣𝑎𝑙𝑢𝑒−𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
× 100   (3.9) 
The MTT assay is a colorimetric assay used to assess the cellular metabolism and inference on 
cellular viability, measuring the activity of cellular enzymes that reduce the thiazolyl blue tetrazolium 
bromide (MTT) substrate, to form insoluble formazan crystals, resulting on a dark purple colour [163]. 
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3.3.9 Permeability studies 
For the permeability experiments, 1×105 cells/cm2 in monocultures of Caco-2 cells and co-cultures 
of Caco-2:HT29-MTX in a proportion of 90:10 were seeded in 12-Transwell® cell culture inserts (pore 
diameter 3.0 µm) and were allowed to grow and differentiate for 21 days with medium replacement 
every other day, as previously optimized by our group [38, 44].  
Before permeability experiments, DMEM was removed from both chambers and the Transwell 
membrane was washed twice with pre-warmed Hank's buffered salt solution (HBSS), then replaced by 
new HBSS and allowed to equilibrate for 30 min at 37 ºC. Permeability studies were run at 37 ºC during 
3 h and with 0.5 mL of PTX-CS-g-PCL 2.5% micelles and free PTX at concentration of 50 µg/mL, both 
prepared in HBSS, were placed in the apical side and 1.5 mL of HBSS in the basolateral side. At 
different time points (15, 30, 45, 60, 90, 120 and 180 minutes), 200 µL of each samples were taken 
from the basolateral side of the inserts and the same volume of fresh HBSS was added to replace the 
withdrawn volume. At the end of the experiment, all volume (0.5 mL) of the apical compartment was 
removed for further analysis. The sample concentrations were quantified by HPLC analysis of PTX 
samples as already described above. 
The integrity of the cell monolayers was checked before the permeability experiment by 
measuring the transepithelial electric resistance (TEER) using Millicell® Electrical Resistance System 
(Millipore, USA). The values were normalized by subtracting the resistance value of the empty insert 
and expressed in ohm per area of the insert (Ω.cm2). The permeability results were expressed in 
percentage of release and apparent permeability (Papp). Papp was calculated using the following 
equation: 
                                           𝑃𝑎𝑝𝑝 =
∆𝑄
𝐴×𝐶0×∆𝑡
      (3.10) 
, where C0 is the initial concentration in the apical compartment (µg/mL), A is the surface area of 
the insert (cm2), ∆𝑡 is the time during which experiment occurred (seconds) and ∆𝑄 is the amount of 
compound detected in the basolateral side (µg). 
3.3.10  Statistical analysis 
All the experiments were performed in triplicate and are represented as mean ± standard 
deviation (SD). A one-way and two-way analysis of variance (ANOVA) with Bonferroni Multiple/Post 
Hoc Group Comparisons (GraphPadPrism software Inc., USA) was used to analyse the data. The level 
of significance was set at probabilities of *p < 0.05, **p < 0.01, and ***p < 0.001.
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Chapter 4 
Results and Discussion 
4.1 Chitosan characterization 
CS is a polysaccharide obtained by partial or complete deacetylation of chitin, and its molecular 
structure and properties are largely affected by the DD. Important properties of biological impact are 
biocompatibility, biodegradation, mucoadhesion, adsorption enhancing, antioxidant capacity, 
hemostatic effect and cell response [160, 164].  Important to notice is that the DD can be replaced 
by the DA, where 𝑫𝑨 = 𝟏𝟎𝟎 − 𝑫𝑫.  
4.1.1 Degree of acetylation 
CS is composed of two far UV chromophoric groups, N-acetyl-D-glucosamine (GlcNAc) and D-
glucosamine (GlcN)  [165].  Because of these groups show no evidence of interacting within the 
polymer in a manner that would affect absorption of UV radiation, the monomer units contribute in 
a simple way to the total absorbance of the material, at a particular wavelength  [165]. 
Determination of the DA of CS by UV spectrophotometry using dual standards is a simple, 
convenient and accurate method to determine the DA of chitosan. However, another method is 
already widely used, which is the first derivative of the UV spectrophotometry offering a simple and 
fast measurement of DA value with good accuracy and precision [158]. Although UV spectra of the 
zero order can be used to measure DA, the first derivative of the spectra is less affected by background 
noise and impurities [166], and so as suggested method [167]. 
The degree of acetylation of the chitosan was determined according to the first derivative 
ultraviolet spectrophotometry method. The spectra of GlcNAc and acetic acid solutions were 
superposed from it is the first derivative (Figure 4.1). 
By overlaying all spectra obtained it is possible to measure the H, in the ordinate axis, which is 
found measuring the distance between the zero crossing point to each GlcNAc concentration, and 
draw a linear calibration curve and determine the equation, linearity and confidence limits (Figure 
4.2). Thus, a linear calibration curve was obtained by plotting the H values against the correspondent 
GlcNAc concentration. 
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Figure 4.1 – First derivative UV-spectra for various concentrations of acetic acid and N-acetyl-D-glucosamine. 
The point where all the acetic acid spectrum cross is the zero crossing point. 
Figure 4.2 – H values as a function of GlcNAc concentration. 
In Figure 4.3 it can be seen the CS spectra plotted overlapped on the Figure 4.1. By measuring 
the value of the CS spectra at 203 nm (zero crossing point), the concentration of GlcNAc in the 
analysed CS sample can be determined by substituting the correspondent H by Y in the obtained 
equation (Figure 4.2). So, the achieved concentration of N-acetyl-D-glucosamine in mg/L is equal to 
the degree of acetylation in wt.% (only valid if the chitosan sample dissolved is exactly 500 mg) [167].  
The DA value (19.27%) can be seen in Table 4.1 as well as the DD, which was calculated through 
the following equation: 
     𝐷𝐷 =  100 − 𝐷𝐴     (4.1) 
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Figure 4.3 – First derivative UV-spectra for a chitosan sample and various concentrations of acetic acid and N-
acetyl-D-glucosamine. 
 
To confirm the results obtained by the previous technique, DA was also determined by NMR 
spectroscopy.  
 In the 1H NMR analysis is possible to find the DA by CH3 (GlcNAc) and H2-H6 (GlcNAc and GlcN) 
areas from the CS spectrum, as can be seen in Figure 4.4, since the NMR shows the complete 
structure of CS. This method consists in using the area under the peak at 2 ppm region assigned to 
the methyl of hydrogen nuclei of the acetamide group (ACH3) and the area of peak attributed to the 
proton attached to C-2 of the glucosamine ring (AH2-H6) as it has already been described [159]. 
Then, the DA was obtained through the substitution of the areas in the Equation 3.1. The DA 
obtained was 18.48%. 
 Figure 4.4 – 1H NMR chitosan spectrum with group’s identification (A) and with calculated areas (B). 
A 
B 
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This means that DD is 81.52%. Table 4.1 summarizes the DD for the chitosan obtained by First 
derivative UV-spectra and 1H NMR. 
 
Table 4.1 — Degree of deacetylation (DD) and degree of acetylation (DA) of chitosan calculated through the 
first derivative spectra and 1H NMR analysis. 
First derivative 1H NMR 
DD (%) 80.73 81.52 
DA (%) 19.27 18.48 
 
Through the analysis of the results, it can be conclude that both techniques had similar results. 
Thus, during this dissertation, the DD of the CS used is about 81%. 
The use of the DD on this range of values is common to other similar studies performed where the 
DD was 85% [84, 168]. As mentioned before, the DD and Mw are important CS features that must be 
known in order to predict physicochemical characteristics such as biocompatibility or 
biodegradability. Besides that, the higher the DD, more free amino groups will be to react with other 
molecules. In this particular case, it is important that the CS had a high DD for free amino groups 
react with the carboxylic groups of PCL. 
4.1.2 Molecular weight 
The Mw of CS was determined by viscometric method [169] at 25 ± 0.1ºC. The relative viscosity, 
η, of CS samples was measured using Ubbelohde capillary viscometer and the intrinsic viscosity [η] of 
CS was calculated using both the Huggins and the Kraemer equations. 
As mentioned earlier, the average of Mw was determined based on the Mark-Houwink equation: η 
= K𝑀𝑣
𝑎, where 𝑘 =  3.5 × 10−4  and 𝑎 =  0.76 [158]. 
The intrinsic viscosity was assumed to be the average between the values obtained from Huggins 
and Kraemer equations. For CS the intrinsic viscosity was 1.993 and based on the Mark-Houwink 
equation, the Mv determined was 87,371 Da, approximately 87 kDa. In Figure 4.5, it is shown the 
Huggins and Kraemer equations with their equations, used to calculate the Mw of CS. 
Figure 4.5 – Plots of the 𝜂𝑠𝑝/𝐶 and 𝑙𝑛(𝜂𝑟𝑒𝑙)/𝐶, from Huggins and Kraemer equations, respectively, versus 
concentration of the chitosan samples. 
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A study performed by Schipper et al. [94], used several types of CS varying their Mw and DD to 
assess how this variation had influence on the absorption of drugs through human epithelial cells. 
Permeability was evaluated in monoculture Caco-2 model. The results showed that CS with low Mw 
(<22 kDa) and high DA (<35%) had little improvement in the absorption of molecules. On the other 
hand, CS with low DA and high Mw increased epithelial permeability [94]. 
It can be concluded that, besides the physical and chemical characteristics dependent of these 
two factors, the improvement of drug absorption by the intestinal epithelium is also dependent of 
them. So, based on these facts, the CS used in this work seems to be the one with the ideal 
characteristics to be as drug carrier in the intestinal epithelium.  
4.2 Synthesis and characterization of chitosan-grafted-
polycaprolactone  
A carbodiimide reaction by amidation was made to reach chitosan-grafted-polycaprolactone (CS-
g-PCL) as shown in Figure 3.1. As described above, from modified PCL with a terminal carboxyl group 
it is possible to graft PCL onto CS backbone using amine coupling agent DCC/NHS at an alkaline pH. 
PCL, with a terminal carboxyl group, is activated with NHS, which is catalyzed with DCC, forming 
polycaprolactone succinimide ester (PCL-NHS). After removing the insoluble by-product, 
dicyclohexylurea, PCL-NHS activated is added to the CS solution is comprised of acetic acid and 
sodium hydroxide to a pH of 7-8. The reaction between two polymers continued at 50 ºC for 24 h. 
4.2.1 NMR analysis 
The chemical structure of CS-g-PCL was verified by 1H NMR analysis. In Figure 4.6A, 4.6B and 
4.6C, it was observed the 1H NMR spectra of CS-g-PCL, PCL and CS, respectively. Four characteristic 
peaks of PCL emerged at 1.4, 1.6-1.7, 2.3, 4.1 ppm, which corresponded to the γ, β and δ, α and ε 
signals of the graft segment in CS-g-PCL copolymer, respectively. The peaks at 3.4-4.0 and 2.05 ppm 
were assigned to 3, 4, 5, 6, 6’ and 7 of pyranose repeat units in CS, respectively.  
The chemical structure of CS-g-PCL was clearly confirmed by the presence of the characteristic 
peaks of CS and PCL in the 1H NMR spectrum [151]. So it could be concluded that CS-g-PCL were 
successfully prepared through carbodiimide reaction by amidation. 
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 Figure 4.6 - 1H NMR spectra of (A) CS-g-PCL in HCl/D2O 1% (v/v), (B) PCL in CDCl3 and (C) CS in HCl/D2O 1% 
(v/v).  
4.2.2 FTIR analysis 
The activation of the terminal carboxylic end groups of the PCL is followed by the formation of 
secondary amide bonds (O=C–NH) between PCL and CS.  
The broad band around 3389 cm-1 corresponded to the contribution of the O–H stretching from 
intra/inter molecular hydrogen bonding and N–H stretching of CS (Figure 4.7C). The peaks at 890 
cm−1 until 1094 cm−1 was assigned to ether groups of the saccharine structures of CS [170]. The peak 
at 1590 cm−1 belongs to the N–H deformations of amino group. The activation of the terminal 
carboxylic end groups of the PCL is followed by the formation of amide bonds (O=C–NH) between PCL 
and CS. For this reason, secondary amide bands were detected at 1650 cm-1 (–C=O stretching) (Figure 
4.7A) [171]. On the other hand, several characteristic bands for PCL (–CO–O–C–) vibrations (Figure 
4.7B) are located at 1725 (–C=O stretching) and the broad band at 2800-3000 cm-1 (Figure 4.7B).  
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The grafted copolymer presented characteristic bands of both CS and PCL and, more importantly, 
is shown the appearance of the new amide bands, result of the reaction of the two polymers, which 
implied the success of the carbodiimide reaction by amidation. 
Figure 4.7 - ATR-FTIR absorbance spectra for detection of surface functional groups. (A) CS-g-PCL copolymer, 
(B) PCL and (C) CS. 
 
NMR and FTIR analysis were performed in order to confirm the formation of the new copolymer. 
The NMR analysis is the most sensitive technique used to determine the structure of a substance. In 
this case, NMR was used in the identification of hydrogen groups of the copolymer. On the other hand, 
FTIR spectroscopy is based on the particular vibrations that each molecule is subjected, corresponding 
to an energy level. This energy depends on factors such as molecular geometry or the mass of atoms 
which is given as an indication of chemical groups presented in a substance [172]. Thus, FTIR analysis 
was used as complementary characterization since it is possible to observe the appearance of the new 
chemical bonds, in this case, the amide bands, result of the reaction of CS amine groups with carboxyl 
groups of PCL. 
4.2.3 Contact angle 
Another technique used to conform the reaction between these two polymers is the contact angle. 
Contact angle technique consists of the measurement of the angle that the drop surface makes with 
a solid, when they contact. The larger the angle is more hydrophobic the surface. An angle of 90-120º 
is considered a hydrophobic surface and an angle greater than 150º is considered a super hydrophobic 
surface. On the other hand, the contact angle low to 90º are considered hydrophilic.  
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As can be seen in Figure 4.8, the contact angle of CS is lower than the copolymer and therefore 
more hydrophilic. As expected, the contact angle of the copolymer is greater than the contact angle 
of the CS, which indicates the presence of the PCL hydrophobic groups in the new copolymer. 
However, this difference is not very strong, which may indicate a low DS of the copolymer. Still, these 
results are in agreement with the literature, where the contact angle of the copolymer is similar to 
the contact angle found by Gu et al., for an average of ε-CL per glucosamine unit in CS of 21.3 [84]. 
Figure 4.8 – Water contact angle of chitosan (A) and CS-g-PCL copolymer (B) after 15 seconds of analysis. 
4.2.4 Critical micelle concentration  
Due to the hydrophobic nature of the PCL and hydrophilic nature of the CS, CS-g-PCL has the 
ability to spontaneously form micelles in aqueous environment. To calculate the concentration at 
which copolymer can form micelles spontaneously, the conductimetric method was employed. The 
CMC was obtained by the meeting point of two lines of the graph of conductivity against the 
logarithmic concentration (Figure 4.9). The CMC obtained was 3.7 × 10−3 mg/mL, which is a result 
according to the literature [5]. 
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Figure 4.9 - Conductivity curve as a function of the log concentration of the copolymer. 
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4.3 Characterization of paclitaxel loaded chitosan-grafted-
polycaprolactone  
The properties and characteristics of the micelles affect the formulation stability, and can 
influence its future interactions with cells and tissues. Thus, aiming to predict the in vivo behavior of 
the developed micelles, their physical-chemical characteristics such as size, polydispersity index 
(PdI), zeta potential, encapsulation efficiency, drug loading and morphology were evaluated. 
4.3.1 Particle size, size distribution and zeta potential 
Several drug masses were tested for the same mass copolymer. Only for the formulation with 5% 
of PTX showed large size when compared with the others. Regarding the PdI and the zeta potential, 
no significant differences were observed when the drug addiction was altered.  
As shown in Table 4.2, for all formulations tested, the size of the micelles varies from a high 
range 408-529 nm. Furthermore, the size of the micelles presented does not vary in proportion to the 
amount of drug added to the formulation and the values presented were high. However, the size of 
the micellar system is not a problem, since the micelles are not internalized by the cells [173]. 
Regarding the PdI, were presented high values in almost all formulations. However, these values 
can be explained by the fact of being micelles mostly made of a natural polymer, CS, where the size 
of the chains cannot be controlled and, therefore, the size of the micelles is very variable.  
All micelles formulations showed positive zeta potential, indicating that micelles were properly 
coated with positively-charged CS. Consistent with previous published data [174, 175], the presence 
of PTX compared with free-drug nanocarriers did not significantly affect the average size and zeta 
potential of the micelles.  
 
Table 4.2 - The particle size, polydispersity index (PdI), -potential and theoretical drug loading of PTX-CS-g-
PCL micelles and CS-g-PCL micelles (empty micelles). Each value represents the mean ± SD of three independent 
measurements (𝑛 = 3). 
Sample Theoretical drug loading (%) Size (nm) PdI ζ-Potential (mV) 
CS-g-PCL - 435±25 0.546±0.160 27.5±1.1 
PTX-CS-g-PCL 0.5 436±35 0.471±0.017 31.7±8.2 
PTX-CS-g-PCL 1.0 427±64 0.501±0.135 33.1±4.1 
PTX-CS-g-PCL 2.5 408±40 0.335±0.021 30.9±3.1 
PTX-CS-g-PCL 5.0 529±33 0.451±0.041 33.3±2.1 
4.3.2 Paclitaxel encapsulation efficiency 
In order to quantify the amount of drug encapsulated in each micelle formulation, as indicated 
above, the quantification was carried out by HPLC. 
A calibration curve to verify the feasibility of the method proposed for this drug analysis was run. 
The patterns for the calibration curve were prepared taking into account the mobile phase of the 
method and also, the solution in which the micelles were prepared. Thus, the preparation of patterns 
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was performed with a total volume of 1 mL, which 80% of volume was methanol and 20% was acetic 
acid 0.1M. The drug concentration used in each pattern ranged from 0.5 µg/mL to 100 µg/mL. In 
Figure 4.10 is possible to observe the calibration curve found. As it can see, the calibration curve 
present a R2=0.9991, which means the method is in perfect conditions, thus feasible to move forward 
in quantification. 
Figure 4.10 - Standard curve calibration for paclitaxel quantification using HPLC. 
 
After the achievement of the calibration curve it was started by injecting the micelles with 
methanol in an attempt to destroy them. However, no peak was observed, indicating no destruction. 
So, it was tried with other solvents such as acetonitrile and chloroform, but remained intact micelles. 
Exhausted the alternatives for quantifying the EE by the direct method, it was moved to the indirect 
method. It means that it was used the resulting supernatants of centrifugation of the micelles, where 
only the non-encapsulated drug were present. Thus, the supernatants were injected and the peaks 
related to PTX appeared. 
The average retention time of PTX is 7.9 minutes. For each peak found, its area was calculated. 
The area value obtained was substituted in calibration curve equation presented above, thereby 
obtaining the concentration of PTX. The EE was calculated from Equation 3.7 and the DL was 
calculated from the Equation 3.8. Table 4.3 presents the theoretical and practical values of DL as 
well as the efficiency of encapsulation. 
 
Table 4.3 - The theoretical and practical drug loading of PTX-CS-g-PCL micelles. Each value represents the mean 
± SD of three independent measurements (𝑛 = 3). 
 
Sample Theoretical drug loading (%) Drug loading (%) Encapsulation efficiency (%) 
PTX-CS-g-PCL 0.5 0.401±0.004 80.6±0.9 
PTX-CS-g-PCL 1.0 0.791±0.062 79.9±6.2 
PTX-CS-g-PCL 2.5 1.995±0.034 81.8±1.4 
PTX-CS-g-PCL 5.0 3.585±0.162 75.3±3.2 
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As can be seen in the table above, the increase of DL was not proportional to the increase of the 
EE. The results indicate that for a range of 0.5-2.5% of the EE is quite similar at around 80%. However, 
when increased DL to 5.0%, the EE decreased slightly, probably due to saturation of the micellar 
system. These results may indicate that due to the degree of substitution for this copolymer, the 
system is not capable to encapsulate more than 2.5-5.0%.  
4.3.3 Transmission electron microscopy 
TEM images (Figure 4.11) were taken to corroborate with micelle size and PdI, as well as assess 
the micellar morphology and PTX encapsulation. TEM microphotographs showed a variability in 
micelles size, justifying the high value of PdI, previously measured by DLS. However, is possible to 
see that most of the micelles found presents sizes smaller than 400 nm. 
These microphotographs also confirms the uniform spherical shape of the micelles before and 
after encapsulation of PTX. The presence of the PTX in micelles did not affect their size as it was had 
already concluded with DLS analysis. 
It is evident the presence of PTX in Figure 4.11B due to the blackening of the inside of the 
micelles, unlike Figure 4.11A, that had a completely white interior. This result confirm the EE 
described above, which is a very good result. 
Figure 4.11 – Transmission electron microscopy images of CS-g-PCL free drug micelles (A) and PTX-CS-g-PCL 
micelles (B) with a scale bar corresponding to 0.5 µm and 1 µm, respectively. 
 
Based on the results obtained in Table 4.2 and 4.3, was chosen drug concentration of 2.5% for 
the subsequent work since it is that presents more advantages in micellar system for drug delivery 
such as smaller size and lower PdI and higher EE.  
4.4 In vitro release studies 
The in vitro release profile of free PTX and PTX-CS-g-PCL micelles was investigated in 0.1% 
Tween®-80 containing PBS (pH 7.4, w/v) at 37 ºC, assuring sink conditions. The cumulative percentage 
release is shown in Figure 4.12.  
As can be observed, 59% of the encapsulated PTX was released from the CS-g-PCL micelles in the 
first hour, despite the difficulty of release in the first time points. This is consistent with other works, 
where is suggested that the drug was entrapped and uniformly distributed in the matrix and thus, 
have more difficult to be released and, consequently, it takes longer [176].  
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When compared the release profile of PTX this micellar system with other drug carrier vehicles, 
it appears that the system developed had a controlled release profile in the first hours, unlike other 
works, where there was a burst release of PTX from the nanoparticles [174, 177]. Also, after 8 hours 
almost all PTX was released from the CS-g-PCL micelles. Already in other works carried out, the PTX 
carrier system used was not able to release all PTX encapsulated [174, 178]. Thus, this system appears 
to be a good approach for controlled release of PTX. 
 On the other hand, the release of the free PTX in the first hour is equivalent to 70.8% of the 
initial amount of PTX placed in the dialysis bag. The amount released is quite similar to the total 
amount of free PTX released (73.9%). As described in the literature [179], the total dissolution of free 
PTX occurs within the first hour of the experiment. However, the same did not happen in this study, 
probably because the sink conditions were not ensured effectively leading to an incomplete 
dissolution of PTX in the medium. 
Figure 4.12 - Cumulative in vitro release of PTX-CS-g-PCL micelles () and free paclitaxel (●) in 0.1% Tween®-
80 containing phosphate-buffered saline (pH 7.4, w/v) at 37 ºC (𝑛 = 3, mean ± SD). 
4.5 Cytotoxicity studies 
In order to evaluate the intestinal safety and biocompatibility of polymers CS, PCL, the new 
copolymer formed (CS-g-PCL), empty micelles and PTX-CS-g-CPL micelles, in vitro experiments using 
Caco-2 and HT29-MTX intestinal epithelial cells were performed. Samples of the above-mentioned 
formulations, and controls of free PTX were incubated with cells for 4 and 24 h and cell viability was 
assessed by MTT assay. 
As depicted in Figure 4.13A and 4.13B, the CS and PCL have no apparent toxicity when incubated 
for 4h in both cell lines at all concentrations. Although there is a slight decrease at the highest 
concentration, it is not biologically relevant. The same trend was observed after incubation for 24 h 
(Figure 4.13C and 4.13D). Regarding to new copolymer, a similar safety profile was observed during 
4h of incubation. Some toxicity was present at concentration of 1000 µg/mL, more evident in HT29-
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MTX cells. After 24 h of incubation, the overt toxicity becomes particularly significant at 
concentration of 1000 µg/mL, reaching a very low level of viability (Figure 4.13C and 4.13D). 
In general, it seems that the concentration had some effect on toxicity only for the copolymer, 
with toxicity for higher concentrations. Similarly, the effect of the incubation time can be evaluated, 
which for 4 h the viability remained similar for all concentrations (except for the highest) and at 24 
h of incubation, the toxicity is more evident for the last three highest concentrations. Regarding the 
potential application of polymeric micelles, and correspondent PTX loading capacity (approximately 
10% w/w), it is not expected significant impact on cell viability. Still, to plan future permeability and 
potential efficacy experiments, it is accept the overall CS-g-PCL concentrations lower than 100 
µg/mL. 
 
Figure 4.13 – Cell viability of chitosan, PCL and CS-g-PCL against Caco-2 (A and C) and HT29-MTX (B and D) cell 
lines, respectively, at concentrations of 0.01-1000 µg/mL after incubation for 4 h (A and B) and for 24 h (C and 
D). Values were reported as mean ± SD (𝒏 = 𝟖). (*), (**), and (***) denotes a significant difference (p<0.05, p<0.01 
and p<0.001), respectively.  
 
As empty micelles demonstrated some toxicity at concentration of 1000 µg/mL, it was decided to 
test the drug loaded micelles at concentrations of 0.01-10 µg/mL range. Additionally, this range of 
concentrations is in line with PTX concentration used in clinic protocols and the plasma levels of the 
drug acceptable for humans [180]. Also, it is noteworthy that this test has not been conducted to 
evaluate the antitumor efficacy of PTX loaded micelles or free PTX, but to assess the safety of 
materials in presence of intestinal cells. Moreover, these tests were performed at very short 
incubation times (4 h and 24 h), which is insufficient time for cell division and, therefore there is no 
intervention of PTX in mitosis. 
Regarding the toxicity at 4 h to either the free drug or loaded micelles (Figure 4.14A and 4.14B) 
no apparent toxicity is shown, despite the small significance found between loaded micelles and free 
drug in Caco-2 cell line (Figure 4.14A). However, after 24 h of incubation (Figure 4.14C and 4.14D), 
there is evidence of decrease in cell viability for PTX concentration higher than 0.1 µg/mL, presenting 
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viability values close to 50% at the highest concentration (10 µg/mL). This result is consistent with 
other works performed [174, 181]. The loaded micelles demonstrated better safety profiles in 
comparison with the free drug, achieving viability values near from 70% to Caco-2 cells and 60% in 
HT29-MTX cells. 
 In summary, the viability decreases with increasing concentration for the both free PTX and PTX-
loaded CS-g-PCL micelles, wherein free drug present more toxicity. Regarding the incubation time, 
there are significant viability difference presented at 4h and 24h. Thus, it is clear that CS-g-PCL 
micelles provide a better safety profile of PTX compared to PTX in solution. 
Figure 4.14 – Cell viability of loaded micelles and free PTX against Caco-2 (A and C) and HT29-MTX (B and D) 
cell lines, respectively, at concentrations of 0.01-10 µg/mL after incubation for 4 h (A and B) and for 24 h (C and 
D). Values were reported as mean ± SD (𝒏 = 𝟖). (*) and (***) denotes a significant difference (p<0.05 and p<0.001), 
respectively.  
4.6 Permeability studies 
One approach to enhance the bioavailability of PTX is to improve its permeability across the 
intestinal barrier. The objective of this set of experiments was to investigate and demonstrate the 
effect of PTX-CS-g-PCL micelles on enhancing the oral absorption of PTX focused on Caco-2 
monoculture model and Caco-2/HT29-MTX co-culture model at physiological proportions (90/10).  
As mentioned previously, cells were seeded for both models and allowed to grow for 21 days. On 
the day of the experiment (day 21), the measurement of TEER was made before the experiment 
(Table 4.4), in order to assess the integrity of the monolayer. Also, the TEER values reflects the 
quality of the TJs. A decrease of TEER manifests opening tight junctions, which means an increase of 
the paracellular permeability [182]. As can be seen in Table 4.4, the TEER values of Caco-2/HT29-
MTX co-culture model had lower values compared with Caco-2 monoculture model. This data indicate 
that the presence of HT29-MTX cells enhance the permeability promoting TJs less tight and, 
consequently, lower TEER values. Thus, the TEER values obtained before the experiment showed that 
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the integrity of the cell monolayers was attained, so are fulfil the conditions necessary to start the 
test.  
 
Table 4.4 - TEER values before the permeability experiment. Each value represents the mean ± SD of three 
independent measurements (𝒏 = 𝟑). 
 
The permeability profile of PTX loaded micelles and free PTX are shown in Figure 4.15 for Caco-
2 monoculture and in Figure 4.16 for Caco-2/HT29-MTX co-culture models. Also, in Figure 4.17 it is 
possible to compare the permeability of the micelles for both models in an attempt to better 
discussion of results. 
As can be observed in Figure 4.15, the permeability of PTX encapsulated in the micelles started 
somewhat later, probably due to the delay in release PTX from micelles. This delay in in agreement 
with the simulated in vitro release profile (Figure 4.12). Nonetheless, the permeability was increased 
to a maximum of 13% permeation, compared to the maximum of 10% obtained to PTX in solution. 
Although the permeability of free PTX was continuous, permeating the epithelium around 7%, 
increasing to nearly 10%. The increased permeability of the PTX-micellar system is also probably due 
to solubility increasing effect provided by nanoencapsulation. The free PTX permeability corresponds 
to a 𝑷𝒂𝒑𝒑 = 𝟒. 𝟐 × 𝟏𝟎−𝟔𝒄𝒎/𝒔𝒆𝒄, which is in the same range of permeability values founded in  
literature for this cell model [183, 184].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 – In vitro cumulative permeability profiles of paclitaxel loaded micelles (▲) and free paclitaxel (○) 
across Caco-2 monoculture model. All experiments were conducted from the apical to basolateral compartment 
in HBSS at 37 ºC. Error bars represent mean ± SD (𝒏 = 𝟑).  
 
Despite initial delay on the permeability of PTX loaded micelles, it was an increase of the micelles 
permeability in the last time point. Perhaps, if the test continued for longer, would verify an increase 
in permeability due to the adhesive nature of the micelles to intestinal cells. In a work developed by 
Mo et al., with micelles based in CS, the Papp 𝟖. 𝟓𝟓 ±  𝟎. 𝟗𝟎 ×  𝟏𝟎−𝟔 cm/s, which was approximately 
TEERCaco-2 (Ω.cm2) TEERco-culture model (Ω.cm2) 
CS-g-PCL micelles Free PTX CS-g-PCL micelles Free PTX 
112±1 101±3 83±2 72±2 
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2-fold improved in comparison with free PTX [182]. The authors relate this increase to the 
mucoadhesive CS character as well as the positive charge of the micelles which promotes the opening 
of tight junctions [185]. 
In an attempt to evaluate the effect of mucus in the permeation of PTX in the intestinal epithelium 
a Caco-2/HT29-MTX co-culture model, previously developed by our group, was used to compare the 
permeability profiles of PTX compare to enterocytes monolayer. As can be seen in Figure 4.16, the 
permeation of PTX for both samples had a similar profile reaching a permeability of 17% and 15% for 
PTX encapsulated and for free PTX, respectively. In general, can be concluded that the co-culture 
model enhances the permeation of either the drug-loaded micelles or the free drug as would be 
expected for this model since, the presence of HT29-MTX cells promote TJs less tight than in Caco-2 
monoculture model [186], thus allowing a permeation slightly higher. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 – In vitro cumulative permeability profiles of paclitaxel loaded micelles (▲) and free paclitaxel (○) 
across Caco-2/HT29-MTX co-culture model. All experiments were conducted from the apical to basolateral 
compartment in HBSS at 37 ºC. Error bars represent mean ± SD (𝒏 = 𝟑).  
 
As can be seen in Figure 4.17, in this model did not occurs a delay in permeation of PTX from the 
micelles, probably due to the presence of mucus, which provided a deeper and faster interaction of 
micelles with epithelial cells. In other words, the mucoadhesive character of CS present in these 
micelles promoted adherence to the mucosal layer of the model, favouring the immediate permeation 
of PTX. Furthermore, it is possible to conclude that the co-culture model presented had the faster 
and higher permeability. As mentioned before, this model is more realistic compared with the human 
intestine through the mucus production, but also due the formation of TJs less tight as Caco-2 
monolayer [38], which means an increase of the paracellular permeability [182].  
At the end of the experiment, the volume of the apical compartment was also collected for later 
analysis. As can be seen in Table 4.5, after analysis by HLPC and PTX quantitation, it was found that 
about 6% of drug present in the micelles was not permeated for the monoculture model and about 7% 
was not permeate the model co-culture. The remaining about 84% of drug to the monoculture model 
and about 76% for the co-culture model must have been retained in the cell layer, adhering to the 
cells. 
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Regarding to the free PTX, about 27% of free drug was not permeated for the monoculture model 
and about 25% for the co-culture model. The remaining about 60% of free drug should probably have 
been retained in the cell monolayer, adhering to the cells. 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 – In vitro cumulative permeability profiles of paclitaxel loaded micelles across Caco-2 monoculture 
model (●) and across Caco-2/HT29-MTX co-culture model (). All experiments were conducted from the apical 
to basolateral compartment in HBSS at 37 ºC. Error bars represent mean ± SD (𝑛 = 3).  
 
Table 4.5 - Apical compartment paclitaxel quantification (%). Each value represents the mean ± SD of three 
independent measurements (𝑛 = 3). 
Apical compartment paclitaxel quantification (%) 
Caco-2 monoculture model Caco-2/HT29-MTX co-culture model 
CS-g-PCL micelles Free PTX CS-g-PCL micelles Free PTX 
5.96±0.99 26.87±1.15 6.91±0.66 25.08±9.77 
 
Indeed, micellar system had more PTX absorbed to cells than free PTX. This possible adhesion can 
be explained by the absorption of the micelles to the cells due to the mucoadhesive character of 
chitosan. These chitosan-based micelles place the anti-cancer drug in deeper contact with cancer 
cells, which may be more effective for the anti-tumor activity.  
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Chapter 5 
Conclusion 
In this work a new copolymer based on chitosan and polycaprolactone was synthetized with 
ability to form micelles by self-assembly. Both polymers were chosen because of their properties, but 
especially chitosan due to its biocompatibility, non-toxicity and mucoadhesion properties. The 
chemical synthesis was a success based on the results of FTIR, NMR and contact angle prove. 
The characterization of the micelle passed through the measurement of average size, which 
for the chosen formulation was 408 ± 40 nm with a polydispersity index of 0.335 ± 0.021, which is 
quite high because the micelles are composed mainly of chitosan, which is a natural polymer and 
where the length of their chains cannot be chosen. The zeta potential showed positive charge of 30.9 
± 3.1 mV, according to the literature. The determination of the encapsulation efficiency of PTX was 
achieved by an indirect method, since there was no possibility to destroy the micelles. Was obtained 
an encapsulation efficiency of about 82% which is a very good result for a theoretical drug loading of 
2.5%. Also, the morphology of the micelles was evaluated and was found a uniform spherical, even in 
the presence of PTX, when compared to the empty micelles. 
For the in vitro tests carried out, it was found that the release profile of PTX in intestinal 
conditions is consistent with the literature. Since the release profile of the micellar system only begins 
30 minutes after contact with the release medium. This may be explained by the fact that the PTX 
have some difficulty to break free of the micelles. The same could have happened in permeability 
studies in Caco-2 monoculture model, where the drug permeated only appears after 30 min. However, 
in both models tested, the micelles have a greater permeation. Furthermore, the Caco-2/HT29-MTX 
coculture model had a greater permeation for the micellar system and for the free drug, which is in 
line with the expected results. Thus, it is expected that the micellar system is a promise, since can 
encapsulate enough amount of drug able to release and can across through the intestinal barrier more 
effectively. 
Finally, the cytotoxicity studies did not show overt toxicity after 4h to either the PTX loaded 
micelles and for the free drug. After 24h, it was found that the viability of both cell lines decreases 
with increasing concentrations of PTX loaded micelles and free PTX. However, the free PTX presents 
higher toxicity, and therefore, the micellar system more suitable for applications in drug delivery.  
In conclusion, the micellar system produced presents diameters and encapsulation efficiency 
convenient to be used as a drug delivery system and assays performed in vitro demonstrate that 
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produced micellar system has a better performance in terms of release in intestinal conditions, 
greater intestinal permeability and even lower toxicity in colorectal cancer cells compared to free 
drug. 
It can, therefore, be assumed that the system may hold promise as a vehicle of drug delivery. 
However, there is always room for improvement, and further, more comprehensive studies must be 
conducted in order to make this system a reality in clinical practice for colorectal cancer therapy. 
5.1 Future perspectives 
Despite all the work, there are always things that can be done in an attempt to improve the 
system under development. The ninhydrin assay is used to determine the degree of substitution of 
chitosan in the copolymer formed. This test is important because the degree of substitution of 
chitosan by hydrophobic groups has an influence in several characteristics, such as micelle size and 
superficial charge. Also, production of micelles varying the chitosan/polycaprolactone ratio may be a 
good approach. Besides the features mentioned above, it has been described that the higher the ratio 
of hydrophobic groups, the higher the encapsulation efficiency [5]. 
Other characterizations of the micelles may also be performed, such as scanning electron 
microscopy or atomic force microscopy to examine the surface morphology of the micelles. This 
micellar system could also be evaluated for their antitumor activity, verifying the efficiency of the 
PTX loaded micelles and the free PTX to interfere with the cell cycle and to induce apoptosis due to 
stabilization of microtubules. Another alternative would be to study the effectiveness of this system 
when encapsulated with other types of drugs such as camptothecin and doxorubicin. 
Finally, the in vivo study for the assessment of biodistribution, safety and therapeutic efficiency 
of this system will be essential to proceed for clinical therapy.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blank page 
 56 
 
References 
[1] T. C. Wehler, S. Hamdi, A. Maderer, C. Graf, I. Gockel, I. Schmidtmann, et al., "Single-agent 
therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no 
benefit of combination therapy," International journal of colorectal disease, vol. 28, pp. 385-
398, 2013. 
[2] A. K. Singla, A. Garg, and D. Aggarwal, "Paclitaxel and its formulations," International journal 
of pharmaceutics, vol. 235, pp. 179-192, 2002. 
[3] M. A. Woodruff and D. W. Hutmacher, "The return of a forgotten polymer—Polycaprolactone 
in the 21st century," Progress in Polymer Science, vol. 35, pp. 1217-1256, 2010. 
[4] B. Khorsand, G. Lapointe, C. Brett, and J. K. Oh, "Intracellular drug delivery nanocarriers of 
glutathione-responsive degradable block copolymers having pendant disulfide linkages," 
Biomacromolecules, vol. 14, pp. 2103-11, Jun 10 2013. 
[5] K. Duan, X. Zhang, X. Tang, J. Yu, S. Liu, D. Wang, et al., "Fabrication of cationic nanomicelle 
from chitosan-graft-polycaprolactone as the carrier of 7-ethyl-10-hydroxy-camptothecin," 
Colloids Surf B Biointerfaces, vol. 76, pp. 475-82, Apr 1 2010. 
[6] A. Sosnik, J. das Neves, and B. Sarmento, "Mucoadhesive polymers in the design of nano-drug 
delivery systems for administration by non-parenteral routes: a review," Progress in Polymer 
Science, vol. 39, pp. 2030-2075, 2014. 
[7] M. Dash, F. Chiellini, R. M. Ottenbrite, and E. Chiellini, "Chitosan—A versatile semi-synthetic 
polymer in biomedical applications," Progress in polymer science, vol. 36, pp. 981-1014, 2011. 
[8] (2015, May 2016). Available: https://www.ine.pt/xportal/xmain?xpgid=ine_main&xpid=INE 
[9] (2012, May 2016). Available: http://globocan.iarc.fr/Default.aspx 
[10] E. Fernandes, J. A. Ferreira, P. Andreia, L. Luís, S. Barroso, B. Sarmento, et al., "New trends 
in guided nanotherapies for digestive cancers: A systematic review," Journal of Controlled 
Release, vol. 209, pp. 288-307, 2015. 
[11] A. S. Thakor and S. S. Gambhir, "Nanooncology: the future of cancer diagnosis and therapy," 
CA: a cancer journal for clinicians, vol. 63, pp. 395-418, 2013. 
[12] P. Ramos and M. Bentires-Alj, "Mechanism-based cancer therapy: resistance to therapy, 
therapy for resistance," Oncogene, vol. 34, pp. 3617-3626, 2015. 
[13] V. Balan, G. Dodi, N. Tudorachi, O. Ponta, V. Simon, M. Butnaru, et al., "Doxorubicin-loaded 
magnetic nanocapsules based on N-palmitoyl chitosan and magnetite: Synthesis and 
characterization," Chemical Engineering Journal, vol. 279, pp. 188-197, 2015. 
[14] X. Xiangyang, L. Ling, Z. Jianping, L. Shiyue, Y. Jie, Y. Xiaojin, et al., "Preparation and 
characterization of N-succinyl-N′-octyl chitosan micelles as doxorubicin carriers for effective 
anti-tumor activity," Colloids and Surfaces B: Biointerfaces, vol. 55, pp. 222-228, 2007. 
[15] J. Zhang, X. G. Chen, Y. Y. Li, and C. S. Liu, "Self-assembled nanoparticles based on 
hydrophobically modified chitosan as carriers for doxorubicin," Nanomedicine: 
Nanotechnology, Biology, and Medicine, vol. 3, pp. 258-265, 2007. 
[16] W. Xun, H.-Y. Wang, Z.-Y. Li, S.-X. Cheng, X.-Z. Zhang, and R.-X. Zhuo, "Self-assembled 
micelles of novel graft amphiphilic copolymers for drug controlled release," Colloids and 
Surfaces B: Biointerfaces, vol. 85, pp. 86-91, 2011. 
[17] G. S. Kwon and K. Kataoka, "Block copolymer micelles as long-circulating drug vehicles," 
Advanced drug delivery reviews, vol. 16, pp. 295-309, 1995. 
[18] K. Kazunori, Y. Masayuki, O. Teruo, and S. Yasuhisa, "Block copolymer micelles as vehicles for 
drug delivery," Journal of Controlled Release, vol. 24, pp. 119-132, 1993. 
57 References 
 
 
[19] G. S. Kwon and M. L. Forrest, "Amphiphilic block copolymer micelles for nanoscale drug 
delivery," Drug development research, vol. 67, pp. 15-22, 2006. 
[20] P. V. Balimane and S. Chong, "Cell culture-based models for intestinal permeability: a 
critique," Drug discovery today, vol. 10, pp. 335-343, 2005. 
[21] R. N. Jaladanki and J.-Y. Wang, "Regulation of gastrointestinal mucosal growth," in 
Colloquium Series on Integrated Systems Physiology: From Molecule to Function, 2011, pp. 
1-114. 
[22] C. Pereira, F. Araújo, C. C. Barrias, P. L. Granja, and B. Sarmento, "Dissecting stromal-
epithelial interactions in a 3D in vitro cellularized intestinal model for permeability studies," 
Biomaterials, vol. 56, pp. 36-45, 2015. 
[23] R. K. Montgomery, A. E. Mulberg, and R. J. Grand, "Development of the human gastrointestinal 
tract: twenty years of progress," Gastroenterology, vol. 116, pp. 702-731, 1999. 
[24] B. Gannon, "The vasculature and lymphatic drainage," Gastrointestinal and oesophageal 
pathology. Edinburgh: Churchill Livingstone, vol. 129, 1995. 
[25] (2015, April 2016). Available: http://www.myvmc.com/anatomy/gastrointestinal-system/ 
[26] M. T. Abreu, "Toll-like receptor signalling in the intestinal epithelium: how bacterial 
recognition shapes intestinal function," Nature Reviews Immunology, vol. 10, pp. 131-144, 
2010. 
[27] A. L. Daugherty and R. J. Mrsny, "Transcellular uptake mechanisms of the intestinal epithelial 
barrier Part one," Pharmaceutical science & technology today, vol. 2, pp. 144-151, 1999. 
[28] L. G. Van der Flier and H. Clevers, "Stem cells, self-renewal, and differentiation in the 
intestinal epithelium," Annual review of physiology, vol. 71, pp. 241-260, 2009. 
[29] M. A. Clark, M. A. Jepson, and B. H. Hirst, "Exploiting M cells for drug and vaccine delivery," 
Advanced drug delivery reviews, vol. 50, pp. 81-106, 2001. 
[30] Y. Yun, Y. W. Cho, and K. Park, "Nanoparticles for oral delivery: targeted nanoparticles with 
peptidic ligands for oral protein delivery," Advanced drug delivery reviews, vol. 65, pp. 822-
832, 2013. 
[31] P. W. Swaan, "Recent advances in intestinal macromolecular drug delivery via receptor-
mediated transport pathways," Pharmaceutical research, vol. 15, pp. 826-834, 1998. 
[32] K. Y. Win and S.-S. Feng, "Effects of particle size and surface coating on cellular uptake of 
polymeric nanoparticles for oral delivery of anticancer drugs," Biomaterials, vol. 26, pp. 2713-
2722, 2005. 
[33] M. Garcia-Fuentes and M. J. Alonso, "Chitosan-based drug nanocarriers: where do we stand?," 
Journal of Controlled Release, vol. 161, pp. 496-504, 2012. 
[34] M.-C. Chen, K. Sonaje, K.-J. Chen, and H.-W. Sung, "A review of the prospects for polymeric 
nanoparticle platforms in oral insulin delivery," Biomaterials, vol. 32, pp. 9826-9838, 2011. 
[35] T. R. Stouch and O. Gudmundsson, "Progress in understanding the structure–activity 
relationships of P-glycoprotein," Advanced drug delivery reviews, vol. 54, pp. 315-328, 2002. 
[36] X. Zhang and W. Wu, "Ligand-mediated active targeting for enhanced oral absorption," Drug 
discovery today, vol. 19, pp. 898-904, 2014. 
[37] A. S Darwich, S. Neuhoff, M. Jamei, and A. Rostami-Hodjegan, "Interplay of metabolism and 
transport in determining oral drug absorption and gut wall metabolism: a simulation 
assessment using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” model," 
Current drug metabolism, vol. 11, pp. 716-729, 2010. 
[38] F. Araújo and B. Sarmento, "Towards the characterization of an in vitro triple co-culture 
intestine cell model for permeability studies," International journal of pharmaceutics, vol. 
458, pp. 128-134, 2013. 
[39] F. Araújo, N. Shrestha, M.-A. Shahbazi, P. Fonte, E. M. Mäkilä, J. J. Salonen, et al., "The 
impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the 
intestinal epithelium," Biomaterials, vol. 35, pp. 9199-9207, 2014. 
[40] M. D. Peterson and M. S. Mooseker, "Characterization of the enterocyte-like brush border 
cytoskeleton of the C2BBe clones of the human intestinal cell line, Caco-2," J Cell Sci, vol. 
102, pp. 581-600, 1992. 
[41] T. Lesuffleur, A. Barbat, E. Dussaulx, and A. Zweibaum, "Growth adaptation to methotrexate 
of HT-29 human colon carcinoma cells is associated with their ability to differentiate into 
columnar absorptive and mucus-secreting cells," Cancer Research, vol. 50, pp. 6334-6343, 
1990. 
[42] P. Artursson, "Cell cultures as models for drug absorption across the intestinal mucosa," 
Critical reviews in therapeutic drug carrier systems, vol. 8, pp. 305-330, 1990. 
58 References 
 
 
 
[43] S. Mouly and M. F. Paine, "P-glycoprotein increases from proximal to distal regions of human 
small intestine," Pharmaceutical research, vol. 20, pp. 1595-1599, 2003. 
[44] F. Antunes, F. Andrade, F. Araújo, D. Ferreira, and B. Sarmento, "Establishment of a triple 
co-culture in vitro cell models to study intestinal absorption of peptide drugs," European 
Journal of Pharmaceutics and Biopharmaceutics, vol. 83, pp. 427-435, 2013. 
[45] I. Behrens, A. I. V. Pena, M. J. Alonso, and T. Kissel, "Comparative uptake studies of 
bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the 
effect of mucus on particle adsorption and transport," Pharmaceutical research, vol. 19, pp. 
1185-1193, 2002. 
[46] C. M. Spencer and D. Faulds, "Paclitaxel. A review of its pharmacodynamic and 
pharmacokinetic properties and therapeutic potential in the treatment of cancer," Drugs, vol. 
48, pp. 794-847, Nov 1994. 
[47] M. F. Carlier and D. Pantaloni, "Taxol effect on tubulin polymerization and associated 
guanosine 5'-triphosphate hydrolysis," Biochemistry, vol. 22, pp. 4814-4822, 1983. 
[48] P. B. Schiff, J. Fant, and S. B. Horwitz, "Promotion of microtubule assembly in vitro by taxol," 
1979. 
[49] (April 2016). The cell cycle, mitosis and meiosis. Available: 
http://www2.le.ac.uk/departments/genetics/vgec/schoolscolleges/topics/cellcycle-
mitosis-meiosis 
[50] Paclitaxel Product Information [Online]. Available: 
https://www.sigmaaldrich.com/content/dam/sigma-
aldrich/docs/Sigma/Product_Information_Sheet/t1912pis.pdf 
[51] S. L. Richheimer, D. M. Tinnermeier, and D. W. Timmons, "High-performance liquid 
chromatographic assay of taxol," Analytical chemistry, vol. 64, pp. 2323-2326, 1992. 
[52] N. A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernäs, A. S. Hussain, et 
al., "Molecular properties of WHO essential drugs and provisional biopharmaceutical 
classification," Molecular pharmaceutics, vol. 1, pp. 85-96, 2004. 
[53] D. M. Vyas, "3 Paclitaxel (taxol®) formulation and prodrugs," Pharmacochemistry Library, vol. 
22, pp. 103-130, 1995. 
[54] J. Szebeni, C. R. Alving, and F. M. Muggia, "Complement activation by Cremophor EL as a 
possible contributor to hypersensitivity to paclitaxel: an in vitro study," Journal of the 
national cancer institute, vol. 90, pp. 300-306, 1998. 
[55] C. Zhang, P. Qineng, and H. Zhang, "Self-assembly and characterization of paclitaxel-loaded 
N-octyl-O-sulfate chitosan micellar system," Colloids and Surfaces B: Biointerfaces, vol. 39, 
pp. 69-75, 2004. 
[56] J. Liebmann, J. Cook, C. Lipschultz, D. Teague, J. Fisher, and J. Mitchell, "Cytotoxic studies 
of paclitaxel (Taxol) in human tumour cell lines," British journal of cancer, vol. 68, p. 1104, 
1993. 
[57] P. Schiff and S. B. Horwitz, "Taxol stabilizes microtubules in mouse fibroblast cells," 
Proceedings of the National Academy of Sciences, vol. 77, pp. 1561-1565, 1980. 
[58] D. e. a. Guenard, Current Pharmaceutical Design, vol. 1, 1995. 
[59] X. Huang, Y. Xiao, and M. Lang, "Self-assembly of pH-sensitive mixed micelles based on linear 
and star copolymers for drug delivery," Journal of colloid and interface science, vol. 364, pp. 
92-99, 2011. 
[60] V. P. Torchilin, "Micellar nanocarriers: pharmaceutical perspectives," Pharm Res, vol. 24, pp. 
1-16, Jan 2007. 
[61] Z. Ahmad, A. Shah, M. Siddiq, and H.-B. Kraatz, "Polymeric micelles as drug delivery vehicles," 
RSC Advances, vol. 4, p. 17028, 2014. 
[62] C. Le Tien, M. Lacroix, P. Ispas-Szabo, and M.-A. Mateescu, "N-acylated chitosan: hydrophobic 
matrices for controlled drug release," Journal of Controlled Release, vol. 93, pp. 1-13, 2003. 
[63] M. Ishihara, M. Fujita, S. Kishimoto, H. Hattori, and Y. Kanatani, "Biological , Chemical , and 
Physical Compatibility of Chitosan and Biopharmaceuticals," in Chitosan-Based Systems for 
Biopharmaceuticals: Delivery, Targeting and Polymer Therapeutics, ed, 2012, p. 500. 
[64] Z. Ahmad, A. Shah, M. Siddiq, and H.-B. Kraatz, "Polymeric micelles as drug delivery vehicles," 
Rsc Advances, vol. 4, pp. 17028-17038, 2014. 
[65] S. Biswas, P. Kumari, P. M. Lakhani, and B. Ghosh, "Recent advances in polymeric micelles 
for anti-cancer drug delivery," Eur J Pharm Sci, Dec 31 2015. 
59 References 
 
 
[66] A. R. Sarasam, "Chitosan- polycaprolactone mixtures as biomaterials - influence of surface 
morphology on cellular activity," Bachelor of Science in Chemical Engineering, Jawaharlal 
Nehru Technological University, 2001. 
[67] M. Labet and W. Thielemans, "Synthesis of polycaprolactone: a review," Chemical Society 
Reviews, vol. 38, pp. 3484-3504, 2009. 
[68] I. Aranaz, R. Harris, and A. Heras, "Chitosan Amphiphilic Derivatives . Chemistry and 
Applications," pp. 308-330, 2010. 
[69] V. P. Torchilin, "Micellar nanocarriers: pharmaceutical perspectives," Pharmaceutical 
research, vol. 24, pp. 1-16, 2007. 
[70] S. Biswas, P. Kumari, P. M. Lakhani, and B. Ghosh, "Recent advances in polymeric micelles 
for anti-cancer drug delivery," European Journal of Pharmaceutical Sciences, 2015. 
[71] G. Kwon, M. Naito, M. Yokoyama, T. Okano, Y. Sakurai, and K. Kataoka, "Block copolymer 
micelles for drug delivery: loading and release of doxorubicin," Journal of Controlled Release, 
vol. 48, pp. 195-201, 1997. 
[72] H. Honarkar and M. Barikani, "Applications of biopolymers I: chitosan," Monatshefte für 
Chemie-Chemical Monthly, vol. 140, pp. 1403-1420, 2009. 
[73] H. Silva, K. Dos Santos, and E. I. Ferreira, "Quitosana: derivados hidrossolúveis, aplicações 
farmacêuticas e avanços," Química Nova, vol. 29, p. 776, 2006. 
[74] F. Araújo, N. Shrestha, P. L. Granja, J. Hirvonen, H. A. Santos, and B. Sarmento, "Safety and 
toxicity concerns of orally delivered nanoparticles as drug carriers," Expert opinion on drug 
metabolism & toxicology, vol. 11, pp. 381-393, 2015. 
[75] I. Aranaz, R. Harris, and A. Heras, "Chitosan amphiphilic derivatives. Chemistry and 
applications," Current Organic Chemistry, vol. 14, p. 308, 2010. 
[76] P. Agrawal, G. J. Strijkers, and K. Nicolay, "Chitosan-based systems for molecular imaging," 
Advanced drug delivery reviews, vol. 62, pp. 42-58, 2010. 
[77] N. Alves and J. Mano, "Chitosan derivatives obtained by chemical modifications for biomedical 
and environmental applications," International journal of biological macromolecules, vol. 43, 
pp. 401-414, 2008. 
[78] S. K. Shukla, A. K. Mishra, O. A. Arotiba, and B. B. Mamba, "Chitosan-based nanomaterials: A 
state-of-the-art review," International journal of biological macromolecules, vol. 59, pp. 46-
58, 2013. 
[79] E. Khor and L. Y. Lim, "Implantable applications of chitin and chitosan," Biomaterials, vol. 
24, pp. 2339-2349, 2003. 
[80] F. Andrade, F. Goycoolea, D. A. Chiappetta, J. das Neves, A. Sosnik, and B. Sarmento, 
"Chitosan-grafted copolymers and chitosan-ligand conjugates as matrices for pulmonary drug 
delivery," International Journal of Carbohydrate Chemistry, vol. 2011, 2011. 
[81] Y.-W. Cho, J. Jang, C. R. Park, and S.-W. Ko, "Preparation and solubility in acid and water of 
partially deacetylated chitins," Biomacromolecules, vol. 1, pp. 609-614, 2000. 
[82] C. Zhang, Y. Ding, L. L. Yu, and Q. Ping, "Polymeric micelle systems of hydroxycamptothecin 
based on amphiphilic N-alkyl-N-trimethyl chitosan derivatives," Colloids and Surfaces B: 
Biointerfaces, vol. 55, pp. 192-199, 2007. 
[83] H. Guo, D. Zhang, C. Li, L. Jia, G. Liu, L. Hao, et al., "Self-assembled nanoparticles based on 
galactosylated O-carboxymethyl chitosan-graft-stearic acid conjugates for delivery of 
doxorubicin," International Journal of Pharmaceutics, vol. 458, pp. 31-38, 2013. 
[84] C. Gu, V. Le, M. Lang, and J. Liu, "Preparation of polysaccharide derivates chitosan-graft-poly 
(ɛ-caprolactone) amphiphilic copolymer micelles for 5-fluorouracil drug delivery," Colloids 
and Surfaces B: Biointerfaces, vol. 116, pp. 745-750, 2014. 
[85] M. A. Hernández-valdepeña, J. Pedraza-chaverri, I. Gracia-mora, R. Hernández-castro, F. 
Sánchez-bartez, J. Nieto-sotelo, et al., "Suppression of the tert -butylhydroquinone toxicity 
by its grafting onto chitosan and further cross-linking to agavin toward a novel antioxidant 
and prebiotic material," vol. 199, pp. 485-491, 2016. 
[86] A. S. Berezin and Y. a. Skorik, "Chitosan-isoniazid conjugates: Synthesis, evaluation of 
tuberculostatic activity, biodegradability and toxicity," Carbohydrate Polymers, vol. 127, pp. 
309-315, 2015. 
[87] L. Yu, X. Yue, R. Yang, S. Jing, and L. Qu, "A sensitive and low toxicity electrochemical sensor 
for 2, 4-dichlorophenol based on the nanocomposite of carbon dots, hexadecyltrimethyl 
ammonium bromide and chitosan," Sensors and Actuators B: Chemical, vol. 224, pp. 241-247, 
2015. 
60 References 
 
 
 
[88] S. Shukla, A. Jadaun, V. Arora, R. K. Sinha, N. Biyani, and V. K. Jain, "In vitro toxicity 
assessment of chitosan oligosaccharide coated iron oxide nanoparticles," Toxicology Reports, 
vol. 2, pp. 27-39, 2015. 
[89] X. Fei Liu, Y. Lin Guan, D. Zhi Yang, Z. Li, and K. De Yao, "Antibacterial action of chitosan 
and carboxymethylated chitosan," Journal of Applied Polymer Science, vol. 79, pp. 1324-
1335, 2001. 
[90] I. Helander, E.-L. Nurmiaho-Lassila, R. Ahvenainen, J. Rhoades, and S. Roller, "Chitosan 
disrupts the barrier properties of the outer membrane of Gram-negative bacteria," 
International journal of food microbiology, vol. 71, pp. 235-244, 2001. 
[91] E. I. Rabea, M. E.-T. Badawy, C. V. Stevens, G. Smagghe, and W. Steurbaut, "Chitosan as 
antimicrobial agent: applications and mode of action," Biomacromolecules, vol. 4, pp. 1457-
1465, 2003. 
[92] T. Kean and M. Thanou, "Biodegradation, biodistribution and toxicity of chitosan," Advanced 
Drug Delivery Reviews, vol. 62, pp. 3-11, 2010. 
[93] C. Chatelet, O. Damour, and A. Domard, "Influence of the degree of acetylation on some 
biological properties of chitosan films," Biomaterials, vol. 22, pp. 261-268, 2001. 
[94] N. G. Schipper, K. M. Vårum, and P. Artursson, "Chitosans as absorption enhancers for poorly 
absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug 
transport across human intestinal epithelial (Caco-2) cells," Pharmaceutical research, vol. 13, 
pp. 1686-1692, 1996. 
[95] J.-K. F. Suh and H. W. Matthew, "Application of chitosan-based polysaccharide biomaterials 
in cartilage tissue engineering: a review," Biomaterials, vol. 21, pp. 2589-2598, 2000. 
[96] T. A. Khan, K. K. Peh, and H. S. Ch’ng, "Reporting degree of deacetylation values of chitosan: 
the influence of analytical methods," J Pharm Pharmaceut Sci, vol. 5, pp. 205-212, 2002. 
[97] H. Zhang and S. H. Neau, "In vitro degradation of chitosan by a commercial enzyme 
preparation: effect of molecular weight and degree of deacetylation," Biomaterials, vol. 22, 
pp. 1653-1658, 2001. 
[98] M. Huang, E. Khor, and L.-Y. Lim, "Uptake and cytotoxicity of chitosan molecules and 
nanoparticles: effects of molecular weight and degree of deacetylation," Pharmaceutical 
research, vol. 21, pp. 344-353, 2004. 
[99] C.-M. Lehr, J. A. Bouwstra, E. H. Schacht, and H. E. Junginger, "In vitro evaluation of 
mucoadhesive properties of chitosan and some other natural polymers," International journal 
of Pharmaceutics, vol. 78, pp. 43-48, 1992. 
[100] M. Liu, J. Zhang, X. Zhu, W. Shan, L. Li, J. Zhong, et al., "Ef fi cient mucus permeation and 
tight junction opening by dissociable “ mucus-inert ” agent coated trimethyl chitosan 
nanoparticles for oral insulin delivery," vol. 222, pp. 67-77, 2016. 
[101] L.-W. Hsu, Y.-C. Ho, E.-Y. Chuang, C.-T. Chen, J.-H. Juang, F.-Y. Su, et al., "Effects of pH on 
molecular mechanisms of chitosan-integrin interactions and resulting tight-junction 
disruptions.," Biomaterials, vol. 34, pp. 784-93, 2013. 
[102] I. F. Uchegbu, M. Carlos, C. McKay, X. Hou, and A. G. Schätzlein, "Chitosan amphiphiles 
provide new drug delivery opportunities," Polymer International, vol. 63, pp. 1145-1153, 
2014. 
[103] K. Sonaje, K.-J. Lin, M. T. Tseng, S.-P. Wey, F.-Y. Su, E.-Y. Chuang, et al., "Effects of 
chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins," 
Biomaterials, vol. 32, pp. 8712-8721, 2011. 
[104] Y. Okamoto, R. Yano, K. Miyatake, I. Tomohiro, Y. Shigemasa, and S. Minami, "Effects of chitin 
and chitosan on blood coagulation," Carbohydrate Polymers, vol. 53, pp. 337-342, 2003. 
[105] S. B. Rao and C. P. Sharma, "Use of chitosan as a biomaterial: studies on its safety and 
hemostatic potential," Journal of biomedical materials research, vol. 34, pp. 21-28, 1997. 
[106] J. Yang, F. Tian, Z. Wang, Q. Wang, Y. J. Zeng, and S. Q. Chen, "Effect of chitosan molecular 
weight and deacetylation degree on hemostasis," Journal of Biomedical Materials Research 
Part B: Applied Biomaterials, vol. 84, pp. 131-137, 2008. 
[107] Y. Ohshima, K. Nishino, Y. Yonekura, S. Kishimoto, and S. Wakabayashi, "Clinical application 
of chitin non-woven fabric as wound dressing," European Journal of Plastic Surgery, vol. 10, 
pp. 66-69, 1987. 
[108] Y. Okamoto, K. Kawakami, K. Miyatake, M. Morimoto, Y. Shigemasa, and S. Minami, "Analgesic 
effects of chitin and chitosan," Carbohydrate Polymers, vol. 49, pp. 249-252, 2002. 
61 References 
 
 
[109] J. C. Fernandes, P. Eaton, H. Nascimento, M. S. Gião, Ó. S. Ramos, L. Belo, et al., "Antioxidant 
activity of chitooligosaccharides upon two biological systems: Erythrocytes and 
bacteriophages," Carbohydrate Polymers, vol. 79, pp. 1101-1106, 2010. 
[110] P.-J. Park, J.-Y. Je, and S.-K. Kim, "Free radical scavenging activities of differently 
deacetylated chitosans using an ESR spectrometer," Carbohydrate Polymers, vol. 55, pp. 17-
22, 2004. 
[111] R. Xing, S. Liu, Z. Guo, H. Yu, P. Wang, C. Li, et al., "Relevance of molecular weight of 
chitosan and its derivatives and their antioxidant activities in vitro," Bioorganic & medicinal 
chemistry, vol. 13, pp. 1573-1577, 2005. 
[112] Y. Kurita and a. Isogai, "Reductive N-alkylation of chitosan with acetone and levulinic acid in 
aqueous media," International Journal of Biological Macromolecules, vol. 47, pp. 184-189, 
2010. 
[113] Y. Kurita and a. Isogai, "N-Alkylations of chitosan promoted with sodium hydrogen carbonate 
under aqueous conditions.," International journal of biological macromolecules, vol. 50, pp. 
741-6, 2012. 
[114] B. E. Benediktsdóttir, T. Gudjónsson, Ó. Baldursson, and M. Másson, "N-alkylation of highly 
quaternized chitosan derivatives affects the paracellular permeation enhancement in 
bronchial epithelia in vitro," European Journal of Pharmaceutics and Biopharmaceutics, vol. 
86, pp. 55-63, 2014. 
[115] K. dos Santos Alves, R. R. Lima Vidal, and R. de Carvalho Balaban, "Chitosan derivatives with 
thickening properties obtained by reductive alkylation," Materials Science and Engineering: 
C, vol. 29, pp. 641-646, 2009. 
[116] K. M. Varum, M. W. Anthonsen, H. Grasdalen, and O. Smidsrod, "Determination of the degree 
of N-acetylation and the distribution of N-acetyl groups in partially N-deacetylated chitins 
(chitosans) by high-field n.m.r. spectroscopy," Carbohydrate Research, vol. 211, pp. 17-23, 
1991. 
[117] I. Tsigos, A. Martinou, D. Kafetzopoulos, and V. Bouriotis, "Chitin deacetylases: New, versatile 
tools in biotechnology," Trends in Biotechnology, vol. 18, pp. 305-312, 2000. 
[118] J. a. D. M. Delezuk, M. B. Cardoso, A. Domard, and S. P. Campana-Filho, "Ultrasound-assisted 
deacetylation of beta-chitin: influence of processing parameters," Polymer International, vol. 
60, pp. 903-909, 2011. 
[119] M. E. I. Badawy, E. I. Rabea, T. M. Rogge, C. V. Stevens, G. Smagghe, W. Steurbaut, et al., 
"Synthesis and Fungicidal Activity of New N , O-Acyl Chitosan Derivatives," pp. 589-595, 2004. 
[120] M. E. I. Badawy, E. I. Rabea, T. M. Rogge, C. V. Stevens, W. Steurbaut, M. Höfte, et al., 
"Fungicidal and insecticidal activity of O-acyl chitosan derivatives," Polymer Bulletin, vol. 54, 
pp. 279-289, 2005. 
[121] A. Pavinatto, A. L. Souza, J. a. M. Delezuk, F. J. Pavinatto, S. P. Campana-Filho, and O. N. 
Oliveira, "Interaction of O-acylated chitosans with biomembrane models: Probing the effects 
from hydrophobic interactions and hydrogen bonding," Colloids and Surfaces B: Biointerfaces, 
vol. 114, pp. 53-59, 2014. 
[122] S. Hirano, Y. Yamaguchi, and M. Kamiya, "Novel N-saturated-fatty-acyl derivatives of chitosan 
soluble in water and in aqueous acid and alkaline solutions," Carbohydrate Polymers, vol. 48, 
pp. 203-207, 2002. 
[123] S. Hirano, Y. Ohe, and H. Ono, "Selective N-acylation of chitosan.," Carbohydrate research, 
vol. 47, pp. 315-320, 1976. 
[124] J. Desbrieres, C. Martinez, and M. Rinaudo, "Hydrophobic derivatives of chitosan: 
characterization and rheological behaviour," International journal of biological 
macromolecules, vol. 19, pp. 21-28, 1996. 
[125] J. Desbrières, C. Martinez, and M. Rinaudo, "Hydrophobic derivatives of chitosan: 
Characterization and rheological behaviour," International Journal of Biological 
Macromolecules, vol. 19, pp. 21-28, 1996. 
[126] M. Rinaudo, R. Auzely, C. Vallin, and I. Mullagaliev, "Specific interactions in modified chitosan 
systems," Biomacromolecules, vol. 6, pp. 2396-2407, 2005. 
[127] M. Larsson, W.-C. Huang, M.-H. Hsiao, Y.-J. Wang, M. Nydén, S.-H. Chiou, et al., "Biomedical 
applications and colloidal properties of amphiphilically modified chitosan hybrids," Progress 
in Polymer Science, vol. 38, pp. 1307-1328, 2013. 
[128] V. Mourya and N. N. Inamdar, "Chitosan-modifications and applications: opportunities galore," 
Reactive and Functional polymers, vol. 68, pp. 1013-1051, 2008. 
62 References 
 
 
 
[129] K. Y. Lee, W. H. Jo, I. C. Kwon, Y.-H. Kim, and S. Y. Jeong, "Physicochemical Characteristics 
of Self-Aggregates of Hydrophobically Modified Chitosans," Langmuir, vol. 14, pp. 2329-2332, 
1998. 
[130] C.-G. G. Liu, K. G. H. DESAI, X.-G. G. Chen, and H.-J. J. Park, "Linolenic acid-modified 
chitosan for formation of self-assembled nanoparticles," Journal of Agricultural and Food 
Chemistry, vol. 53, pp. 437-441, 2005. 
[131] Y. Hu, Y. Du, J. Yang, Y. Tang, J. Li, and X. Wang, "Self-aggregation and antibacterial activity 
of N-acylated chitosan," Polymer, vol. 48, pp. 3098-3106, 2007. 
[132] G.-B. Jiang, D. Quan, K. Liao, and H. Wang, "Preparation of polymeric micelles based on 
chitosan bearing a small amount of highly hydrophobic groups," Carbohydrate Polymers, vol. 
66, pp. 514-520, 2006. 
[133] K. Kurita, "Controlled functionalization of the polysaccharide chitin," Progress in Polymer 
Science (Oxford), vol. 26, pp. 1921-1971, 2001. 
[134] W. Sui, Y. Changqing, C. Yanjing, Z. Zhiguo, and K. Xiangzheng, "Self-assembly of an 
amphiphilic derivative of chitosan and micellar solubilization of puerarin," Colloids and 
Surfaces B: Biointerfaces, vol. 48, pp. 13-16, 2006. 
[135] L. Martin, C. G. Wilson, F. Koosha, L. Tetley, A. I. Gray, S. Senel, et al., "The release of model 
macromolecules may be controlled by the hydrophobicity of palmitoyl glycol chitosan 
hydrogels.," Journal of controlled release : official journal of the Controlled Release Society, 
vol. 80, pp. 87-100, 2002. 
[136] C. Zhang, G. Qu, Y. Sun, X. Wu, Z. Yao, Q. Guo, et al., "Pharmacokinetics, biodistribution, 
efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel," 
Biomaterials, vol. 29, pp. 1233-1241, 2008. 
[137] M. Wiens, T. A. Elkhooly, H. C. Schroder, T. H. Mohamed, and W. E. Muller, "Characterization 
and osteogenic activity of a silicatein/biosilica-coated chitosan-graft-polycaprolactone," Acta 
Biomater, vol. 10, pp. 4456-64, Oct 2014. 
[138] H. Tian, Z. Tang, X. Zhuang, X. Chen, and X. Jing, "Biodegradable synthetic polymers: 
Preparation, functionalization and biomedical application," Progress in Polymer Science, vol. 
37, pp. 237-280, 2012. 
[139] Y. Lu, L. Liu, and S. Guo, "Novel amphiphilic ternary polysaccharide derivates chitosan-g-PCL-
b-MPEG: synthesis, characterization, and aggregation in aqueous solution," Biopolymers, vol. 
86, pp. 403-8, Aug 5-15 2007. 
[140] S. Zamani and S. Khoee, "Preparation of core–shell chitosan/PCL-PEG triblock copolymer 
nanoparticles with ABA and BAB morphologies: Effect of intraparticle interactions on 
physicochemical properties," Polymer, vol. 53, pp. 5723-5736, 2012. 
[141] A. P. D. Elfick, "Poly(e-caprolactone) as a potential material for a temporary joint spacer," 
Biomaterials, vol. 23, pp. 4463–4467, 2002. 
[142] T. Elzein, M. Nasser-Eddine, C. Delaite, S. Bistac, and P. Dumas, "FTIR study of 
polycaprolactone chain organization at interfaces," J Colloid Interface Sci, vol. 273, pp. 381-
7, May 15 2004. 
[143] A. J. Sawdon and C. A. Peng, "Ring-opening polymerization of epsilon-caprolactone initiated 
by ganciclovir (GCV) for the preparation of GCV-tagged polymeric micelles," Molecules, vol. 
20, pp. 2857-67, 2015. 
[144] S. Sahoo, A. Sasmal, D. Sahoo, and P. Nayak, "Synthesis and characterization of chitosan-
polycaprolactone blended with organoclay for control release of doxycycline," Journal of 
Applied Polymer Science, vol. 118, pp. 3167-3175, 2010. 
[145] L. S. Nair and C. T. Laurencin, "Biodegradable polymers as biomaterials," Progress in Polymer 
Science, vol. 32, pp. 762-798, 2007. 
[146] D. L. Wise, Encyclopedic Handbook of Biomaterials and Bioengineering: v. 1-2. Applications: 
CRC Press, 1995. 
[147] O. Coulembier, P. Degée, J. L. Hedrick, and P. Dubois, "From controlled ring-opening 
polymerization to biodegradable aliphatic polyester: Especially poly(β-malic acid) 
derivatives," Progress in Polymer Science, vol. 31, pp. 723-747, 2006. 
[148] D. Mondal, M. Griffith, and S. S. Venkatraman, "Polycaprolactone-based biomaterials for 
tissue engineering and drug delivery: Current scenario and challenges," International Journal 
of Polymeric Materials and Polymeric Biomaterials, vol. 65, pp. 255-265, 2016. 
63 References 
 
 
[149] R. F. Storey and A. Taylor, "Effect of stannous octoate concentration on the ethylene glycol-
initiated polymerization of epsilon-caprolactone," in ABSTRACTS OF PAPERS OF THE AMERICAN 
CHEMICAL SOCIETY, 1996, p. 114. 
[150] V. K. Thakur and M. K. Thakur, "Eco-friendly Polymer Nanocomposites," 2015. 
[151] H. Yu, W. Wang, X. Chen, C. Deng, and X. Jing, "Synthesis and characterization of the 
biodegradable polycaprolactone‐graft‐chitosan amphiphilic copolymers," Biopolymers, vol. 
83, pp. 233-242, 2006. 
[152] S. C. Neves, L. S. M. Teixeira, L. Moroni, R. L. Reis, C. A. Van Blitterswijk, N. M. Alves, et al., 
"Chitosan/Poly (ɛ-caprolactone) blend scaffolds for cartilage repair," Biomaterials, vol. 32, 
pp. 1068-1079, 2011. 
[153] Z. Wang, L. Zheng, C. Li, D. Zhang, Y. Xiao, G. Guan, et al., "A novel and simple procedure 
to synthesize chitosan-graft-polycaprolactone in an ionic liquid," Carbohydr Polym, vol. 94, 
pp. 505-10, Apr 15 2013. 
[154] G. Cai, H. Jiang, Z. Chen, K. Tu, L. Wang, and K. Zhu, "Synthesis, characterization and self-
assemble behavior of chitosan-O-poly (ε-caprolactone)," European Polymer Journal, vol. 45, 
pp. 1674-1680, 2009. 
[155] C. Gu, V. Le, M. Lang, and J. Liu, "Preparation of polysaccharide derivates chitosan-graft-
poly(varepsilon-caprolactone) amphiphilic copolymer micelles for 5-fluorouracil drug 
delivery," Colloids Surf B Biointerfaces, vol. 116, pp. 745-50, Apr 1 2014. 
[156] H. Feng and C.-M. Dong, "Preparation and characterization of chitosan-graft-poly (ϵ-
caprolactone) with an organic catalyst," Journal of Polymer Science Part A: Polymer 
Chemistry, vol. 44, pp. 5353-5361, 2006. 
[157] L. Liu, Y. Wang, X. Shen, and Y. Fang, "Preparation of chitosan-g-polycaprolactone copolymers 
through ring-opening polymerization of epsilon-caprolactone onto phthaloyl-protected 
chitosan," Biopolymers, vol. 78, pp. 163-70, Jul 2005. 
[158] R. A. Muzzarelli and R. Rocchetti, "Determination of the degree of acetylation of chitosans by 
first derivative ultraviolet spectrophotometry," Carbohydrate Polymers, vol. 5, pp. 461-472, 
1985. 
[159] R. Signini and S. P. Campana Filho, "Purification and characterization of commercial chitosan," 
Polímeros, vol. 8, pp. 63-68, 1998. 
[160] M. R. Kasaai, "A review of several reported procedures to determine the degree of N-
acetylation for chitin and chitosan using infrared spectroscopy," Carbohydrate Polymers, vol. 
71, pp. 497-508, 2008. 
[161] M. Wiens, T. A. Elkhooly, H.-C. Schröder, T. H. Mohamed, and W. E. Müller, "Characterization 
and osteogenic activity of a silicatein/biosilica-coated chitosan-graft-polycaprolactone," Acta 
biomaterialia, vol. 10, pp. 4456-4464, 2014. 
[162] S. Nsereko and M. Amiji, "Localized delivery of paclitaxel in solid tumors from biodegradable 
chitin microparticle formulations," Biomaterials, vol. 23, pp. 2723-2731, 2002. 
[163] T. Mosmann, "Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays," Journal of immunological methods, vol. 65, pp. 55-63, 
1983. 
[164] I. Aranaz, M. Mengíbar, R. Harris, I. Paños, B. Miralles, N. Acosta, et al., "Functional 
characterization of chitin and chitosan," Current Chemical Biology, vol. 3, pp. 203-230, 2009. 
[165] D. Liu, Y. Wei, P. Yao, and L. Jiang, "Determination of the degree of acetylation of chitosan 
by UV spectrophotometry using dual standards," Carbohydrate research, vol. 341, pp. 782-
785, 2006. 
[166] H. Y. Hsiao, C. C. Tsai, S. Chen, B. C. Hsieh, and R. L. Chen, "Spectrophotometric 
determination of deacetylation degree of chitinous materials dissolved in phosphoric acid," 
Macromolecular bioscience, vol. 4, pp. 919-921, 2004. 
[167] S. C. Tan, E. Khor, T. K. Tan, and S. M. Wong, "The degree of deacetylation of chitosan: 
advocating the first derivative UV-spectrophotometry method of determination," Talanta, 
vol. 45, pp. 713-719, 1998. 
[168] Z. Wang, L. Zheng, C. Li, D. Zhang, Y. Xiao, G. Guan, et al., "A novel and simple procedure 
to synthesize chitosan-graft-polycaprolactone in an ionic liquid," Carbohydrate polymers, vol. 
94, pp. 505-510, 2013. 
[169] C. R. Huei and H.-D. Hwa, "Effect of molecular weight of chitosan with the same degree of 
deacetylation on the thermal, mechanical, and permeability properties of the prepared 
membrane," Carbohydrate polymers, vol. 29, pp. 353-358, 1996. 
64 References 
 
 
 
[170] A. Sionkowska, M. Wisniewski, J. Skopinska, C. Kennedy, and T. Wess, "Molecular interactions 
in collagen and chitosan blends," Biomaterials, vol. 25, pp. 795-801, 2004. 
[171] P. Hendra, W. Maddams, I. Royaud, H. Willis, and V. Zichy, "The application of Fourier 
transform Raman spectroscopy to the identification and characterization of polyamides—I. 
Single number nylons," Spectrochimica Acta Part A: Molecular Spectroscopy, vol. 46, pp. 747-
756, 1990. 
[172] P. R. Griffiths and J. A. De Haseth, Fourier transform infrared spectrometry vol. 171: John 
Wiley & Sons, 2007. 
[173] L. Mu and S. Feng, "A novel controlled release formulation for the anticancer drug paclitaxel 
(Taxol®): PLGA nanoparticles containing vitamin E TPGS," Journal of controlled release, vol. 
86, pp. 33-48, 2003. 
[174] F. Danhier, N. Lecouturier, B. Vroman, C. Jérôme, J. Marchand-Brynaert, O. Feron, et al., 
"Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation," 
Journal of Controlled Release, vol. 133, pp. 11-17, 2009. 
[175] M. Garinot, V. Fiévez, V. Pourcelle, F. Stoffelbach, A. des Rieux, L. Plapied, et al., "PEGylated 
PLGA-based nanoparticles targeting M cells for oral vaccination," Journal of Controlled 
Release, vol. 120, pp. 195-204, 2007. 
[176] A. Potineni, D. M. Lynn, R. Langer, and M. M. Amiji, "Poly (ethylene oxide)-modified poly (β-
amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery," 
Journal of Controlled Release, vol. 86, pp. 223-234, 2003. 
[177] Z. Wei, J. Hao, S. Yuan, Y. Li, W. Juan, X. Sha, et al., "Paclitaxel-loaded Pluronic P123/F127 
mixed polymeric micelles: formulation, optimization and in vitro characterization," 
International journal of pharmaceutics, vol. 376, pp. 176-185, 2009. 
[178] T. Yang, M.-K. Choi, F.-D. Cui, J. S. Kim, S.-J. Chung, C.-K. Shim, et al., "Preparation and 
evaluation of paclitaxel-loaded PEGylated immunoliposome," Journal of Controlled Release, 
vol. 120, pp. 169-177, 2007. 
[179] C. Wang, Y. Wang, Y. Wang, M. Fan, F. Luo, and Z. Qian, "Characterization, pharmacokinetics 
and disposition of novel nanoscale preparations of paclitaxel," International journal of 
pharmaceutics, vol. 414, pp. 251-259, 2011. 
[180] E. Raymond, A. Hanauske, S. Faivre, E. Izbicka, G. Clark, E. K. Rowinsky, et al., "Effects of 
prolonged versus short-term exposure paclitaxel (Taxol (R)) on human tumor colonyforming 
units," Anti-cancer drugs, vol. 8, pp. 379-385, 1997. 
[181] L. Zhang, Y. He, G. Ma, C. Song, and H. Sun, "Paclitaxel-loaded polymeric micelles based on 
poly (ɛ-caprolactone)-poly (ethylene glycol)-poly (ɛ-caprolactone) triblock copolymers: in 
vitro and in vivo evaluation," Nanomedicine: Nanotechnology, Biology and Medicine, vol. 8, 
pp. 925-934, 2012. 
[182] R. Mo, X. Jin, N. Li, C. Ju, M. Sun, C. Zhang, et al., "The mechanism of enhancement on oral 
absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles," Biomaterials, vol. 32, pp. 
4609-4620, 2011. 
[183] U. K. Walle and T. Walle, "Taxol transport by human intestinal epithelial Caco-2 cells," Drug 
metabolism and disposition, vol. 26, pp. 343-346, 1998. 
[184] E. Roger, F. Lagarce, E. Garcion, and J.-P. Benoit, "Lipid nanocarriers improve paclitaxel 
transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis," 
Journal of Controlled Release, vol. 140, pp. 174-181, 2009. 
[185] Y.-H. Lin, F.-L. Mi, C.-T. Chen, W.-C. Chang, S.-F. Peng, H.-F. Liang, et al., "Preparation and 
characterization of nanoparticles shelled with chitosan for oral insulin delivery," 
Biomacromolecules, vol. 8, pp. 146-152, 2007. 
[186] N. Li, D. Wang, Z. Sui, X. Qi, L. Ji, X. Wang, et al., "Development of an improved three-
dimensional in vitro intestinal mucosa model for drug absorption evaluation," Tissue 
Engineering Part C: Methods, vol. 19, pp. 708-719, 2013. 
  
 
 
 
 
 
 
